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ABSTRACT 
Pancreatic ductal adenocarcinoma (PDAC), one of the most aggressive human 
malignancies, is thought to be initiated by KRAS activation. Here, we find that 
transcriptional activation mediated by the GLI family of transcription factors, 
although dispensable for pancreatic development, is required for KRAS induced 
pancreatic transformation. Inhibition of GLI using a dominant-negative repressor 
(Gli3T) inhibits formation of precursor Pancreatic Intraepithelial Neoplasia (PanIN) 
lesions in mice, and significantly extends survival in a mouse model of PDAC. 
Further, ectopic activation of the GLI1/2 transcription factors in mouse pancreas 
accelerates KRAS driven tumor formation and reduces survival, underscoring the 
importance of GLI transcription factors in pancreatic tumorigenesis. Interestingly, 
we find that although canonical GLI activity is regulated by the Hedgehog ligands, 
in the context of PDAC, GLI transcription factors initiate a unique ligand-
independent transcriptional program downstream of KRAS, that involves 
regulation of the RAS, PI3K/AKT, and NF-кB pathways. 
We identify I-kappa-B kinase epsilon (IKBKE) as a PDAC specific target of GLI, 
that can also regulate GLI transcriptional activity via positive feedback mechanism 
involving regulation of GLI subcellular localization. Using human PDAC cells, and 
an in vivo model of pancreatic neoplasia, we establish IKBKE as a novel regulator 
pf pancreatic tumorigenesis that acts as an effector of KRAS/GLI, and mediates 
pancreatic transformation. We show that genetic knockout of Ikbke leads to a 
dramatic inhibition of initiation and progression of pancreatic intraepithelial 
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neoplasia (PanIN) lesions in mice carrying pancreas specific activation of 
oncogenic Kras. Furthermore, we find that although IKBKE is a known NF-кB 
activator, it only modestly regulates NF-кB activity in PDAC. Instead, we find that 
IKBKE strongly promotes AKT phosphorylation in PDAC in vitro and in vivo, and 
that IKBKE mediates reactivation of AKT post-inhibition of mTOR. We also show 
that while mTOR inhibition alone does not significantly affect pancreatic 
tumorigenesis, combined inhibition of IKBKE and mTOR has a synergistic effect 
leading to significant decrease tumorigenicity of PDAC cells.  
Together, our findings identify GLI/IKBKE signaling as an important oncogenic 
effector pathway of KRAS in PDAC that regulates tumorigenicity, cell proliferation, 
and apoptosis via regulation of AKT and NF-кB signaling. We provide proof of 
concept for therapeutic targeting of GLI/IKBKE in PDAC, and support the 
evaluation of IKBKE as a therapeutic target in treatment of pancreatic cancer, and 
IKBKE inhibition as a strategy to improve efficacy of mTOR inhibitors in the clinic.  
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Pancreatic Ductal Adenocarcinoma (PDAC) is the most common type of 
pancreatic cancer, accounting for over 90% of all pancreatic malignancies1. PDAC 
is among the most aggressive malignancies, with a 5 year survival rate of less than 
5%2. PDAC accounts for over 40,000 deaths in the US every year, and by 2020, it 
is predicted to become the second leading cause of cancer deaths3. Surgery 
remains the only potentially curative option for PDAC, however, a majority of the 
patients present with unresectable, and metastatic disease at the time of 
diagnosis4. PDAC is also highly refractory to conventional chemotherapy, and the 
lack of effective treatment options results in a dismal survival rate5.   
PDAC treatment and prognosis 
Surgery is the most important treatment option for PDAC, and is known to 
significantly improve patient survival. Pancreaticoduodenectomy (Whipple 
procedure), the core surgical treatment for patients with pancreatic cancer can  
increase 5 year survival rates to over 20%, and median survival to over 24 months 
in PDAC patients6,7. However, only 15-20% of patients are considered eligible for 
surgery8. Even after surgical resection, prognosis is poor due to localized 
recurrence of the tumors, and also distant metastases due to microscopic 
disease9. 
A majority of the PDAC patients, who are not eligible for surgery, are treated with 
cytotoxic chemotherapy. The nucleoside analogue Gemcitabine has been used as 
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the standard chemotherapeutic agent in treatment of PDAC. Prior to Gemcitabine, 
5’-Fluorouracil (5’-FU) was used in treating patients, however, Gemcitabine was 
shown to have a modest survival benefit when compared to 5’-FU (median survival 
5.6 vs 4.4 months) in patients with advanced PDAC10. Gemcitabine treatment also 
resulted in a significantly improved 1 year survival rate of 18%, compared to 2% in 
patients treated with 5’-FU. Furthermore, the median time to progressive disease 
in patients treated with Gemcitabine was 9 weeks, compared to 4 weeks in patients 
treated with 5’-FU. Patients treated with Gemcitabine also showed a significant 
decrease in pain intensity, with 23.8% patients experiencing decreased pain 
compared to 4.8% of patients treated with 5’-FU.  
Recently, a combination therapy of Oxaliplatin, Irinotecan, Leucovorin, and 5’-FU 
(FOLFIRINOX) was shown to have a significant survival benefit compared to  
Gemcitabine (median survival 11.1 months vs 6.8 months with Gemcitabine) in 
patients with metastatic pancreatic cancer11. However, due to higher toxicity and 
side effects compared to Gemcitabine, only patients with good performance status 
(ECOG 0-1) are eligible for FOLFIRINOX treatment. Combining Gemcitabine with 
Nab-Paclitaxel has recently been shown to improve survival (median survival of 
8.5 months vs 6.7 months with Gemcitabine alone), and is a standard treatment 
for patients with advanced PDAC12. Paclitaxel is a taxane that interferes with 
microtubule assembly, and acts as an inhibitor of mitosis13. Nab-Paclitaxel (Nano 
particle Albumin-bound Paclitaxel) is an albumin-stabilized paclitaxel formulation 
that enables delivery of the hydrophobic Paclitaxel, and was developed to reduce 
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cytotoxicity associated with other solvents used for Paclitaxel delivery14. Data 
comparing FOLFIRINOX treatment with Gemcitabine/Nab-Paclitaxel has not been 
published, and this clinical trial is currently underway (NCT01488552). Currently, 
both FOLFIRINOX, and Gemcitabine/Nab-Paclitaxel are considered standard 
treatment options for patients with advanced PDAC.  
Chemotherapeutic agents are also used in adjuvant therapy for patients with 
resectable PDAC. In patients treated with surgery, Gemcitabine treatment post-
resection was shown to significantly improve prognosis (median disease free 
survival of 13.4 months vs 6.9 months in the control arm)15. A clinical trial 
evaluating the benefit of FOLFIRINOX as adjuvant therapy in resectable PDAC is 
currently underway (NCT01660711). The potential for pre-operative neo-adjuvant 
chemotherapy in resectable PDAC is also being evaluated. A previous study has 
shown that patients treated with Gemcitabine in combination with Cisplatin before 
surgery had higher rates of resection (70%) compared to patients treated with 
Gemcitabine alone (38%), and patients treated with combination therapy also 
showed a higher rate of 1 year survival (62%) compared to patients treated with 
Gemcitabine alone (42%)16. A recent study has also shown that patients treated 
with pre-operative Gemcitabine based chemoradiotherapy showed increased 
median survival (45 months) compared to patients treated with surgery alone (23.5 
months)17. Treatment with 5’-FU or Gemcitabine based chemoradiation prior to 
surgery has also shown to improve median survival as well as increased 
resectability, and decreased lymph node metastasis18. Further clinical trials 
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evaluating the efficacy of neoadjuvant chemotherapy in PDAC are currently 
underway (NCT01900327, NCT01521702, NCT01771146, NCT02148549).  
Targeted therapies for PDAC have also been evaluated. Combination of 
Gemcitabine with the VEGF inhibitor Bevacizumab failed to improve patient 
outcome compared with treatment with Gemcitabine alone19. The farnesyl 
transferase inhibitor Tipifarnib, when used in combination with Gemcitabine failed 
to show benefit in extending patient survival20. Combination of Gemcitabine with 
the Hedgehog pathway inhibitor IPI-296 was found be to be less beneficial 
compared with the Gemcitabine plus placebo arm, and the trial was discontinued 
(NCT01130142). The HER2 inhibitor Herceptin, when tested in combination with 
Gemcitabine in metastatic PDAC with HER2 overexpression failed to provide 
clinical benefit21. mTOR inhibitors Everolimus, and Temsirolimus have also failed 
to show efficacy in PDAC22,23. The EGFR inhibitor Erlotinib, when combined with 
Gemcitabine, showed a modest, but statistically significant survival benefit 
compared to Gemcitabine treatment alone (6.24 months vs 5.91)24. Experiments 
in mouse models have shown that while EGFR inhibition using monoclonal 
antibodies, Erlotinib, or genetic knockout can impair acinar-to-ductal metaplasia, 
and initiation of tumorigenesis, this requirement can be bypassed by inactivation 
of p5325. Additional studies in mice have shown that EGFR signaling may be 
mediated by PI3K and STAT3, and tumor explants lacking p53 and EGFR were 
sensitive to PI3K and STAT3 combined inhibition, thus highlighting potential 
benefit in combined inhibition of EGFR, PI3K, and STAT326. Currently, Erlotinib is 
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the only targeted therapy agent approved for treatment of PDAC, however the use 
of Erlotinib in combination with other targeted therapy agents needs to be further 
evaluated. Clinical trials testing efficacy of targeted therapeutics against other 
candidates such as PARP (NCT01585805), CCR2 (NCT01413022), AKT 
(NCT01783171), Aurora A Kinase (NCT01924260), and CTLA4 (NCT02311361) 
are currently underway. 
While cytotoxic chemotherapy, and targeted therapy using Erlotinib has been 
shown to improve prognosis, and quality of life in PDAC patients, the overall 
survival benefit accorded by these treatments is modest, and a majority of the 
patients succumb to the disease within 1 year of diagnosis, even with treatment. 
In order to reduce the high rate of mortality associated with PDAC, there is a need 
to develop additional treatment options, and gain better insight into the 
mechanisms underlying the initiation, progression, and metastasis of PDAC.  
Pathology of Pancreatic Cancer 
PDAC arises through early precursor lesions called pancreatic intraepithelial 
neoplasia (PanIN). Histologically, these lesions are graded as PanIN1, PanIN2, or 
PanIN3 with increasing order of severity respectively27. PanIN1 lesions have a flat 
or papillary mucinous epithelium without cellular atypia. PanIN2 lesions have 
cellular atypia with predominantly papillary architecture. PanIN3 lesions resemble 
carcinoma in situ, and show increased cellular and nuclear atypia, as well luminal 
invasion28. In genetically modified mouse models, it has been shown that PanIN 
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lesions can arise from multiple cell types in the pancreas including ductal cells, 
islets, and acini29. In the presence of oncogenic mutations in KRAS, and chronic 
inflammation, non-ductal cells such as islets, and acini have been shown to 
undergo reprogramming into a “duct-like” cell type before initiating PanIN lesion 
formation in mouse models (Figure 1.1)30. PanIN lesions subsequently progress to 
full blown adenocarcinoma, and metastatic cancer, with the most common sites of 
metastasis being the liver and lungs2.  
In addition to the epithelial component, the tumor microenvironment, consisting of 
stromal and immune cells is a significant component of PDAC tumors. One feature 
of PDAC is a high degree of desmoplastic reaction surrounding the tumor cells31. 
Major components of the stroma in PDAC are the pancreatic stellate cells, 
fibroblasts, and immune cells32. Paracrine signals from the epithelium are known 
to activate the desmoplastic reaction and promote stromal proliferation33,34. 
Stromal proliferation has been shown to be promoted by Sonic Hedgehog ligand 
secretion by the epithelium35. The stromal microenvironment surrounding the 
epithelium in PDAC plays an important role in tumor growth and response to 
therapy36.  In transplantation models, it has been shown that stromal depletion 
using inhibitors of the Hedgehog pathway activator Smoothened can lead to 
decrease in tumor growth, and ectopic expression of Sonic Hedgehog in 
pancreatic epithelial cells can promote stromal proliferation37,35. In another study, 
it was shown that treatment with the Smoothened inhibitor Cyclopamine led to a 
statistically significant increase in survival of mice with PDAC (67 days with 
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treatment vs 61 days in vehicle38. In a mouse model of PDAC with oncogenic 
KRAS activation and p53 loss, it was shown that stromal depletion using a 
Smoothened inhibitor can lead to increased vasculature in the tumors, and improve 
delivery of chemotherapeutic agents, which leads to improved survival in the 
mice39.  
Although pancreatic desmoplasia was previously thought to promote tumor 
growth, it has recently been shown that depletion of the stroma in PDAC mouse 
models leads to more aggressive tumors. In a genetically modified mouse model 
of PDAC, it was shown that deletion of Sonic Hedgehog can accelerate tumor 
formation and decrease survival40. In this study, it was also shown that inhibition 
of Smoothened using a small molecule inhibitor IPI-926 resulted in decreased 
desmoplasia, and acceleration of tumor formation and decreased survival, which 
was consistent with earlier findings about Smoothened inhibition in the clinic. The 
tumors with depleted stroma were shown to have increased vasculature and poor 
differentiation. These findings indicate that the stroma may play a role in restricting 
tumor growth by maintaining differentiation of the tumors, and blocking 
angiogenesis. Additional mouse experiments have shown that genetic depletion of 
myofibroblasts can lead to accelerated tumor growth, however, in this model it was 
shown that depletion of the stroma leads to decreased angiogenesis in the tumors, 
which is in contrast to the findings with Sonic Hedgehog deletion41. In this model, 
it was shown that regulatory T-cell (Treg) infiltration is increased in tumors with 
myofibroblast depletion, thus leading to increased immunosuppression, and the 
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acceleration of tumor growth, which was rescued by treatment with a monoclonal 
antibody targeting CTLA4. However, the two models discussed above utilize 
different genetic approaches to develop PDAC tumors, with the Sonic Hedgehog 
depletion study using Trp53 deletion as a strategy, and the myofibroblast study 
utilizing TGF-β depletion to achieve PDAC formation. Further experiments are 
warranted to elucidate the role of the stroma in PDAC and the underlying 
mechanisms. 
PDAC tumors have a high infiltration of immune cells, which contribute to 
inflammation. Inflammation, and immune cell infiltration play a tumor promoting in 
PDAC42. In the initial stages of transformation of pancreatic cells, inflammation in 
the context of  KRAS activation  can accelerate PanIN lesion formation43. Also, 
NF-кB mediated inflammation in PDAC has been shown to amplify KRAS activity 
through positive feedback mechanisms in a mouse model of PDAC44. Cytokine 
secretion by immune cells is known to promote cell survival and apoptosis evasion 
by tumor cells45. Another mechanism by which immune cell infiltration promotes 
PDAC growth is via suppression of immune surveillance. In many types of solid 
tumors, infiltration of tumors by effector T cells is often associated with improved 
clinical outcomes. However, in pancreatic cancer, there is evidence to suggest that 
KRAS activation in the epithelium leads to preferential recruitment of 
immunosuppressive macrophages, myeloid cells, and regulatory T-cells, that in 
turn suppress effector T-cell function in the tumor microenvironment46. These 
findings are consistent with data that suggests that reversion of 
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immunosuppression using CD40 agonists produced significant clinical response in 
patients47. Also, inhibition of Regulatory T-cells in PDAC using an anti-CTLA4 
monoclonal antibody has been shown to cause significant tumor reduction and 
increased survival in a mouse model of PDAC48. Together these findings highlight 
a key role played by immune cell infiltration, and inflammation in the PDAC tumor 
microenvironment. 
Genetics of PDAC 
A number of genetic alterations and signaling events have been identified, that 
mediate initiation of the PanIN lesions, and their progression to full blown 
adenocarcinoma through regulation of the associated cell survival, apoptosis 
evasion, and desmoplastic and inflammatory response (Figure 1.1). 
PDAC is known to be hereditary in a minority of cases. Genetic disorders such as 
Peutz-Jeghers syndrome, melanoma pancreatic cancer syndrome, hereditary 
breast-ovarian cancer syndrome, and familial adenomatous polyposis syndrome 
are associated with an increased risk of pancreatic cancer49. Inherited mutations 
in genes such as BRCA1, BRCA2, PALB2, ATM, and CKDNA2A, which are 
associated with genetic disorders are also known to increase the risk of pancreatic 
cancer. Although certain genetic mutations can predispose patients to PDAC, in a 
majority of cases, PDAC is thought to arise sporadically through somatic 
mutations. Oncogenic activation of KRAS is a universal feature in PDAC, and 
KRAS is mutated in >90% of PDAC cases50. The most common mutations are 
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located at codon G12 (>98% cases), which inhibit the intrinsic GTPase activity of 
the protein, and cause constitutive activation of KRAS51,52. KRAS activation is 
considered to be an initiating event for PDAC, as somatic mutations in KRAS are 
detected even in early neoplastic lesions, and targeting of an oncogenic allele of 
Kras to the pancreas in mouse models has been shown to be sufficient in initiating 
PanIN neoplasms that phenocopy the pancreatic transformation and 
tumorigenesis in human patients53,54. KRAS is also required for progression and 
maintenance of PDAC tumorigenesis, as it has been shown in a mouse model that 
turning off expression of an inducible oncogenic allele of Kras in mice with 
established pancreatic neoplasms led to regression of the neoplasia55.  
While oncogenic activation of KRAS leads to initiation of PanIN lesions and 
pancreatic transformation, loss of tumor suppressors is required for progression to 
full blown adenocarcinoma and metastasis. A number of tumor suppressors have 
been shown to be inactivated in PDAC patients. The most common loss of function 
alterations are found in the tumor suppressors TP53, INK4A/ARF, and SMAD456. 
TP53 missense mutations are found in ~50% of PDAC cases57. TP53 missense 
mutations can act in a dominant-negative manner, and accumulation of the mutant 
p53 protein contributes to evasion of growth arrest in cells and causes metastasis 
in a mouse model of PDAC58.   
Genetic alterations in the tumor suppressor INK4A/ARF are identified in 80-95% 
of PDAC cases, and homozygous deletions in the locus are detected in ~40% of 
cases59,60.The INK4A/ARF locus encodes tumor suppressors p16 and p14. P16 
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acts as an inhibitor of the Cyclin dependent kinases CDK4 and CDK6, which 
mediate G1 to S phase transition via phosphorylation and inhibition of RB.  p14 
inhibits MDM2 mediated degradation of p53, thus leading to increased p53 levels. 
INK4A/ARF can induce senescence through activation of RB and p5361. 
Homozygous deletion of the Ink4a/Arf locus in combination with oncogenic Kras 
has been shown to significantly accelerate tumor formation, and decrease survival 
in a mouse model of PDAC62. Ink4a/Arf deletion can also promote metastasis, and 
recently it has been suggested that this loss of tumor suppressor may also 
contribute to EMT63. Ink4a/Arf loss with oncogenic KRAS has also been shown to 
activate Notch and NF-кB signaling in PDAC64. 
Genetic alterations in SMAD4, a critical component of the TGF-β pathway, are 
identified in ~50% of PDAC cases65. The TGF-β pathway is known to play a tumor 
suppressor role. Earlier studies have shown that a majority of PDAC cases carry 
deletions at chromosome 18q21.1, which encodes the SMAD4 gene, and cases 
with intact 18q21.1 carry mutations in the SMAD4 gene, thus implicating SMAD4 
as a candidate tumor suppressor66. The SMAD4 protein acts as a positive regulator 
of the TGF- β pathway, and inactivation of SMAD4 may promote tumorigenesis by 
inhibiting TGF-β activity. In a mouse model with oncogenic KRAS activation, 
Smad4 homozygous deletion has been shown to dramatically accelerate tumor 
formation and mortality67. 
A recent study involving large scale analysis of human PDAC samples, as well as 
functional characterization using the Sleeping Beauty transposon system in mice, 
 13 
 
and shRNA knockdown in cell lines has led to the identification of previously 
uncharacterized genomic alterations in PDAC, that may contribute towards 
tumorigenicity68. Alterations in a number of genes involved in axon guidance were 
identified in this study along with alterations in genes involved in chromatin 
modification, and DNA damage response. Subsequent studies have also 
implicated the SLIT-ROBO axon guidance pathway in migration and metastasis in 
PDAC69. Further analysis of of these newly identified genomic alterations in PDAC 
is necessary in order to obtain insight into their role in tumorigenesis. 
The oncogenic activation of KRAS, along with subsequent loss of tumor 
suppressors cooperates in progression of PanIN precursor lesions to full blown 
adenocarcinoma, and metastatic PDAC. While KRAS oncogenic mutation, and 
theloss of tumor suppressors is essential for pancreatic tumorigenesis, a number 
of downstream signaling events mediate the process of pancreatic transformation 
and tumorigenesis. 
Signaling pathways in PDAC 
In addition to genetic alterations in oncogenes and tumor suppressors, another 
feature of PDAC is the aberrant activation and misregulation of signaling pathways. 
Among these are pathways such as RAS, NF-кB, RAF/MEK/ERK, 
PI3K/AKT/mTOR, and Hedgehog/GLI signaling, that are known to play a role in 
transformation, apoptosis evasion, inflammation, and development.  
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RAS signaling  
RAS proteins are small GTPases that play a central role in signal transduction. 
The three mammalian RAS proteins HRAS, NRAS, and  KRAS share a high 
degree of homology, and are frequently mutated in cancers70. As discussed 
previously, KRAS is the most frequently mutated gene in pancreatic cancer, and 
activating mutations in KRAS, specifically the KRASG12D mutation, are found in a 
majority of PDAC cases. Normal KRAS protein cycles between the GTP-bound 
active form and the GDP-bound inactive form. Transition to the active GTP-bound 
form is mediated by guanine exchange factors (GEFs), and the switch to GDP-
bound is mediated by the intrinsic GTPase activity of the KRAS protein. Mutations 
found in PDAC at Glycine-12 inhibit the intrinsic GTPase activity of KRAS, thus 
leading to constitutive activation of the oncogene50.  
Under normal conditions, RAS proteins drive a signaling cascade that recruits a 
number of effector pathways such as RAF/MEK/ERK PI3K/AKT, RALGDS, 
RASSF, RIN, and PLCε71. These pathways connect  RAS to biological processes 
such as cell proliferation, differentiation, apoptosis, and senescence72. Constitutive 
activation of KRAS leads to misregulation of these signaling pathways, and the 
related biological processes, which can cause oncogenic transformation. In 
addition to its role in cell proliferation, and survival, oncogenic KRAS  has recently 
been shown to also regulate inflammation, and metabolic rewiring in PDAC73,74. 
KRAS initiated metabolic rewiring enables cancer cells to utilize an alternative 
pathway to metabolize glutamine, which is required for cell proliferation.  
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The RAS effector pathways RAF/MEK/ERK, and PI3K/AKT are known to play an 
important role in mediating pancreatic transformation. In addition to the normal 
RAS effector pathways, oncogenic KRAS can also regulate other signaling 
pathways that are not normally associated with RAS signaling such as NF-кB, and 
Hedgehog/GLI. Together, these effector pathways mediate RAS signaling, and 
oncogenic transformation in pancreatic cancer. KRAS can be considered a master 
regulator of pancreatic cancer due to its requirement in initiation, and progression 
of the disease, as well as its central role in regulating the signaling cascade that 
drives tumorigenicity. Although conceptually KRAS is an attractive therapeutic 
target for PDAC treatment, efforts made to target KRAS with small molecules have 
been largely unsuccessful. One reason for this is that the RAS proteins lack well 
defined binding pockets for small molecules75. Recently, there have been some 
developments in small molecule based RAS inhibition. Molecules that can bind to 
RAS and disrupt its association with the RAS-GEF SOS have been identified76. 
Although these molecules have been shown to successfully inhibit RAS activity in 
biochemical assays, and in cell culture, the dosage required to achieve this effect 
is high, which is a challenge for their use in in vivo models. Recently, small 
molecules that can preferentially bind to the oncogenic mutant form of KRAS 
(G12C) have also been reported77. These molecules were shown to inhibit KRAS 
activity and induce apoptosis and decrease cell viability in lung cancer cell lines. 
While this is a significant development towards RAS targeted therapy, the 
molecules identified in the study are shown to specifically bind to the Cysteine 
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residue at codon 12 in the mutant KRAS, which may limit their potential for use in 
treatment of PDAC, as the KRASG12C mutation is observed in only ~2% of PDAC 
cases78. The potential for these inhibitors in the treatment of this subset of PDAC 
cases may still be evaluated, and the MiaPaca-2 human PDAC cell line, which 
carries the KRASG12C mutation, may be used as a preliminary model for this 
purpose. Another approach that has been evaluated is the inhibition of farnesyl 
transferase inhibitors (FTIs), that inhibit the association KRAS with the cell 
membrane79. However, these inhibitors have been unsuccessful, as KRAS can 
utilize an alternative mechanism dependent on geranylgeranylation to localize to 
the membrane80. An alternative approach in targeted therapy for PDAC is to 
identify, and target effector pathways that are essential for KRAS mediated 
pancreatic transformation.  
RAF/MEK/ERK 
The RAF/MEK/ERK pathway, is a key downstream mediator of EGFR and RAS 
signaling that has been implicated in many cancers81. RAF activation is initiated 
by the association of the N-terminal RAF binding domain (RBD) of the protein with 
the active GTP-bound form of RAS82. There are three RAF isoforms: ARAF, BRAF, 
and CRAF. RAF proteins are kinases that phosphorylate and activate MEK1/2, 
which in turn can activate ERK1/2 via phosphorylation83. Under normal 
circumstances, RAF/MEK/ERK couples signals from the cell surface to 
transcription factors through a process that is tightly regulated84. Deregulation of 
the RAF/MEK/ERK pathway can occur either through somatic mutations of 
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pathway components, or through abnormal activation of upstream signaling 
components such as EGFR or RAS85. Aberrant activation of the RAF/MEK/ERK 
pathway is known to drive cell proliferation, cell survival, and metastasis during 
oncogenic transformation86. The RAF/MEK/ERK pathway has been successfully 
targeted in melanoma, and pathway inhibitors have been approved for use in the 
clinic87,88. Oncogenic BRAF mutations have been identified in melanoma, lung 
cancer, and thyroid cancer89. While activating mutations in BRAF (V599E) have 
been identified in a small subset of KRAS wild type PDAC cases, mutations in the 
RAF/MEK/ERK pathway are rare in PDAC, and the primary mechanism of pathway 
activation is upstream regulation by KRAS90,91.  
In a mouse model of PDAC, constitutive BRAF activation has been shown to 
phenocopy KRAS oncogenic activation92. Inhibition of the RAF/MEK/ERK pathway 
using small molecules can also induce growth arrest in pancreatic cancer cells93. 
Inhibition of this pathway was also shown to sensitize tumors to Gemcitabine in a 
xenograft model of PDAC94. Recently, treatment with a MEK inhibitor was shown 
to decrease tumor growth in a patient derived xenograft model of pancreatic 
cancer95. Due to the importance of the RAF/MEK/ERK pathway in KRAS mediated 
transformation, and the success of pathway inhibitors in the clinic, further studies 
are warranted in order to evaluate the efficacy of inhibition of this pathway in 
pancreatic cancer. 
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PI3K/AKT/mTOR 
The PI3K/AKT/mTOR pathway is commonly deregulated in cancer, and plays an 
important role in regulating cellular processes such as cell proliferation, 
senescence, apoptosis, and metabolism96,97. PI3 Kinases are lipid kinases that 
phosphorylate the inositol 3’-OH group in inositol phospholipids. There are three 
classes of PI3Ks, of which Class I is most commonly implicated in cancer. Class I 
PI3Ks consist of a regulatory subunit, and a catalytic subunit. Three mammalian 
genes, PIK3R1, PIK3R2, and PIK3R3, encode p85α, p85β, and p55γ regulatory 
subunits, respectively. The genes PIK3CA, PIK3CB, and PIK3CD encode the 
catalytic isoforms p110α, p110β, and p110δ98. Class I PI3Ks phosphorylate 
phosphatidylinositol-4,5-bisphosphate (PIP2) to generate the secondary 
messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3)99. PI3Ks are known to 
be activated by receptor tyrosine kinases (RTKs) in response to extracellular 
signals100. PI3Ks can also be activated by RAS independently of RTKs101.  
PI3K mediated conversion of PIP2 to PIP3 can lead to the activation of various 
downstream signaling cascades. The most well characterized effector of PI3K 
signaling is the Serine/Threonine kinase AKT, which has been implicated in many 
cancers and plays an important role in apoptosis evasion and metabolism102. PIP3 
can bind to the pleckstrin homology (PH) domains of AKT and the kinase PDK1, 
and PDK1 in turn activates AKT via phosphorylation at Threonine-308103. The 
activity of PI3K can be countered by the tumor suppressor PTEN. PTEN is a 
phosphatase that converts PIP3 to PIP2, thus preventing AKT phosphorylation104. 
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Under normal conditions, the activation of AKT by PI3K is a tightly controlled 
process, which is regulated by upstream signals and also negative regulators such 
as PTEN105. In cancer, genetic alterations in PI3K, RAS, and PTEN commonly 
result in abnormal activation of AKT106. AKT2 is also amplified in a minority of 
PDAC cases107. 
AKT is phosphorylated at the Serine-473 residue in the hydrophobic motif of the 
C-terminal tail by the mTOR kinase. Phosphorylation at Serine-473 is believed to 
precede phosphorylation at Threonine-308, and contribute to AKT activation108. 
The mTOR kinase is a component of two functionally distinct protein complexes: 
mTORC1, and mTORC2. The mTORC1 complex plays an important role in 
ribosomal biogenesis and protein synthesis. The mTORC2 complex is involved in 
regulation of cell proliferation, survival, apoptosis, and metabolism109. Activation of 
AKT is the most well characterized function of the mTORC2 complex, and is known 
to play a central role in cancer.   
Therapeutic inhibition of mTOR is currently being evaluated as targeted therapy in 
treatment of various malignancies. The mTOR inhibitors Temsirolimus and 
Everolimus have shown significant benefit in treatment of Renal Cell Carcinoma 
and have been approved by the FDA110. mTOR inhibitors have also been 
successful in combination therapy for HER2 negative breast cancer, and also for 
treating subependymal giant cell astrocytoma (SEGA), and have received FDA 
approval111,112. In a mouse model of PDAC, the mTOR inhibitor Rapamycin was 
shown to induce tumor regression in the background of oncogenic Kras combined 
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with Pten loss, but not Trp53 loss113. Recently, Everolimus was also approved for 
treatment of Pancreatic Neuroendocrine Tumors (PNET) following clinical trials 
that showed a significant survival benefit114. PNET, a less aggressive tumor which 
makes up a small minority of all pancreatic malignancies, arises from the islet cells 
and is distinct from PDAC at the pathological, and molecular level. While 
Everolimus showed efficacy in treatment of PNET, one consequence of treatment 
with the drug was upregulation of AKT activation in the tumors115. Everolimus 
specifically inhibits the mTORC1 complex, but not the mTORC2 complex. 
Inhibition of the mTORC1 complex leads to activation of the receptor tyrosine 
kinase (RTK) IGF-1 as a consequence of relieved negative feedback, which in turn 
causes AKT activation116. Since AKT activity plays an important role in PDAC, 
specific mTORC1 inhibition may not be a good strategy in targeting mTOR 
signaling. One potential solution to this problem may be to use dual PI3K/mTOR 
inhibitors, as RTK activation of AKT is mediated by PI3K. However, in order to 
consider this approach, feedback activation of AKT in PDAC, and the potential role 
of RTKs/PI3K in this process in the context of PDAC needs to be further analyzed. 
Second generation mTOR kinase inhibitors that act as ATP competitive inhibitors, 
and target both mTORC1 and mTORC2 are currently being evaluated in clinical 
trials117. Inhibition of both mTORC1 and mTORC2 using mTOR kinase inhibitors 
may be beneficial in preventing feedback activation of AKT. Due to their potential 
in targeting both AKT activation and also other significant biological processes, 
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and their success in treating PDAC in preclinical mouse models, further research 
into the efficacy of mTOR inhibitors in treatment of PDAC is warranted. 
NF-кB 
The NF-кB signaling pathway plays an important role in the regulation of cell 
survival, proliferation and apoptosis, and is a critical mediator of the immune 
response, and inflammation. The NF-кB family of transcription factors consists of 
p65 (RELA), RELB, C-REL, p50/p105, and p52/p100118. In the unstimulated state, 
the NF-кB transcription factors bind to IкB proteins, which sequester the 
transcription factors in the cytoplasm, thus inactivating them119. There are two NF-
кB signaling pathways in cells: the canonical NF-кB signaling pathway, and the 
non-canonical NF-кB signaling pathway. Canonical NF-кB activation is mediated 
primarily by the IкB Kinases (IKK) IKKα and IKKβ. In response to activation of 
upstream receptors, adaptor proteins such as TRAFs and RIPs recruit an IKK 
complex consisting of IKKα, IKKβ, and NEMO (IKKγ). IKKα and IKKβ are activated 
by NEMO, and in turn phosphorylate the IкB repressor at two Serine residues, 
which in turn leads to K48-ubiquitination mediated proteosomal degradation of IкB. 
Degradation of IкB leads to nuclear translocation of the NF-кB transcription factors, 
which in turn drive expression of the NF-кB target genes120. In the non-canonical 
NF-кB pathway, upstream signals such as cytokines lead to activation of the NF-
кB Inducing Kinase (NIK). NIK phosphorylates and activates homodimers of IKKα, 
which in turn phosphorylate p100 leading to its partial proteolysis and release of 
the p52/RELB complex which drives transcription of NF-кB target genes120. The 
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NF-кB pathway can also be activated by atypical IкB kinases IKKε (IKBKE) and 
TBK1. IKBKE and TBK1, which share a high degree of homology with each other, 
but not with the other IKK kinases, are activated in a NEMO independent manner. 
Both IKBKE and TBK1 can phosphorylate IкB, and also play an important role in 
interferon signaling. IKBKE can also directly phosphorylate and activate the 
transcription factor RELA (p65)121. 
Aberrant NF-кB signaling has been implicated in a number of malignancies. The 
oncogenic properties of NF-кB signaling derive from its ability to regulate 
processes involved in cancer such as cell proliferation, and apoptosis. NF-кB 
mediated inflammation has also been shown to contribute to the development of 
cancer122. Canonical NF-кB signaling has been shown to be activated in response 
to oncogenic KRAS activation in PDAC. In a mouse model, it was shown that 
Caerulin induced chronic inflammation can lead to significant upregulation of the 
activity of mutant KRAS in the pancreas44. In this study, the activity of the NF-кB 
activator IKKβ was found to be essential for inflammation induced pancreatic 
transformation in the presence of oncogenic KRAS. Furthermore, it was found that 
treatment with an inhibitor of COX2, an NF-кB target gene, led to loss of 
inflammation induced KRAS activation, thus highlighting a role for NF-кB mediated 
feedback activation of KRAS. In a mouse model of PDAC with Kras activation and 
Ink4a/Arf deletion, genetic ablation of IKKβ was shown to significantly extend 
survival and impair tumorigenesis123. IKKβ deletion resulted in significant reduction 
of pancreatic neoplasia initiation, and decrease in expression of pro-inflammatory 
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cytokines, as well as lymphocyte infiltration. In the same study, it was shown that 
KRAS oncogenic activation could regulate activity of the AP-1 transcription factors, 
which in turn drove expression of the cytokine IL1α, and p62 which results in 
upstream activation of IKKβ. Pancreatitis is known to be a risk factor in PDAC124. 
These findings highlight a potential mechanism through which inflammation may 
lead to feedback activation of oncogenic KRAS, and how pro-inflammatory stimuli 
and NF-κB pathway activity may promote a positive feedback loop which leads to 
sustained NF-κB signaling. Also, these findings provide proof of concept for 
therapeutic targeting of the canonical NF-κB signaling pathway in PDAC. 
Recent studies have also indicated that non-canonical NF-кB signaling mediated 
by constitutive NIK activation may regulate cell proliferation in PDAC cells125. 
Chronic inflammation, which is a feature of PDAC, can upregulate NF-кB signaling 
in PDAC cells in the presence of oncogenic KRAS , which in turn leads to further 
cytokine production by the epithelial cells, and immune cell infiltration in the 
tumors126. In human PDAC cells, KRAS activation is known to upregulate the 
expression of the kinase GSK3α, which activates the canonical NF-kB pathway by 
promoting association of the TAK1 kinase with TAB1, which leads to activation of 
IKK. GSK3α has also been shown to activate the non-canonical NF-кB pathway 
downstream of KRAS by promoting processing of p100, and nuclear accumulation 
of p52. Inhibition of GSK3α can inhibit growth of human PDAC explants127. Since 
GSK3α has been shown to activate both the canonical as well as non-canonical 
NF-кB in the context of oncogenic KRAS, small molecule based GSK3α should be 
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further evaluated as a therapeutic strategy for targeting NF-кB signaling and 
tumorigenicity in PDAC. 
Hedgehog/GLI 
The Hedgehog/GLI Signaling pathway is a crucial developmental pathway that 
regulates multiple processes during embryonic development, and adult tissue 
homoeostasis128. Components of this pathway in mammals include the ligands 
Sonic Hedgehog (SHH), Indian Hedgehog (IHH), and Desert Hedgehog (DHH). 
Secreted Hedgehog ligands bind to their cellular receptor Patched1 (PTCH1), 
which is a 12 transmembrane domain protein. The binding of Hedgehog to 
Patched1 leads to loss of repression of Smoothened (SMO), a 7 pass 
transmembrane surface protein, by Patched1129. Activated Smoothened initiates 
an intracellular signaling cascade that leads to the activation and nuclear 
translocation of the GLI family of transcription factors, which in turn drive the 
expression of Hedgehog target genes. The GLI family of transcription factors 
includes the zinc finger proteins GLI1, GLI2, and GLI3. The GLI proteins possess 
context dependent repressor and activator functions. GLI1 and GLI2 function 
mostly as transcriptional activators, whereas GLI3 functions mostly as a 
transcriptional repressor (Figure 1.2)130.  
Aberrant activation of the Hedgehog signaling pathway was first identified in Basal 
Cell Carcinoma (BCC). Inactivating mutations in Patched1, which lead to a loss of 
repression of Smoothened and constitutive activation of the pathway, have been 
identified in ~90% of the cases of Basal Cell Carcinoma131. Activating mutations in 
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Smoothened have also been identified in BCC. The role of aberrant Hedgehog 
signaling in multiple human malignancies became apparent with the discovery that 
Gorlin Syndrome, a rare genetic condition in which the patients develop multiple 
BCCs during their lifetimes, and are also predisposed to other cancers such as 
Medulloblastoma, and Rhabdomyosarcoma, is characterized by a loss of function 
mutation in Patched1132. One third of all human medulloblastoma cases involve 
upregulation of hedgehog signaling due to mutations in the pathway 
components133. These findings in human patients have been confirmed by 
genetically engineered mouse models in which ectopic expression of SHH, GLI1, 
or GLI2, and constitutively active Smoothened led to the development of 
BCC134,135. Apart from the classical Hedgehog associated cancers, aberrant 
Hedgehog Signaling has been found to play a role in a variety of other 
malignancies such as breast cancer, prostate cancer, melanoma, lung cancer, and 
pancreatic cancer136.  
Hedgehog/GLI Signaling in Pancreatic Tumorigenesis  
While Indian Hedgehog is expressed in the developing pancreas, Sonic Hedgehog 
expression is undetectable. SHH plays a role in restricting pancreatic growth, as 
knockout of SHH leads to expansion of pancreatic mass, and overgrowth of 
endocrine cells137. In contrast, ectopic expression of SHH in the pancreas under 
the control of the Pdx1 promoter leads to disruption of normal development, and 
conversion of pancreatic mesoderm to intestinal mesenchyme138. While Sonic 
Hedgehog (SHH) ligand is normally not expressed in adult pancreas, it is 
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expressed in PanIN lesions in mice carrying oncogenic KRAS, and increased SHH 
expression correlates with increasing histological grades of the lesions (PanIN 1-
3), and also in full blown adenocarcinoma139. During development, in the 
gastrointestinal tract, Hedgehog ligand secreted by the epithelium signals to the 
mesenchyme in a paracrine manner and drives mesenchymal proliferation140. 
Non-canonical GLI signaling, in which GLI transcription factors act independently 
of upstream Hedgehog/Smoothened activity in a cell autonomous manner has also 
been reported in other contexts141. In pancreatic cancer Hedgehog/GLI activity has 
been reported to be regulated through paracrine, autocrine, as well as non-
canonical mechanisms. 
Ligand dependent Hedgehog/GLI signaling: 
The paracrine model for Hedgehog signaling in pancreatic tumorigenesis proposes 
that Hedgehog ligands secreted by the pancreatic tumor epithelium signal to the 
mesenchyme, and drive expression of Hedgehog responsive genes in the 
mesenchyme (Figure 1.3). It has been shown that in xenograft mouse models, 
tumor cells obtained from human patients were capable of driving Hedgehog target 
gene expression in the mouse stroma and that expression of these target genes 
in the stroma correlated with SHH and IHH secretion by the tumor cells37. Genetic 
ablation or chemical antagonist mediated inhibition of Smoothened in the mouse 
stroma also resulted in inhibition of tumor growth in the xenograft models. Also, 
Hedgehog target gene expression has been reported in the mesenchyme, and 
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activation of smoothened in the pancreatic epithelium was not sufficient to induce 
neoplasia.  
According to the autocrine model, Hedgehog ligands secreted by the tumor 
epithelium signal to the epithelial cells and drive hedgehog pathway activation in 
the epithelium to promote tumorigenesis (Figure 1.4). It has been shown that 
treatment of PDAC cell lines with Cyclopamine results in increased apoptosis, and 
decreased proliferation in cells in culture as well as in xenograft models139. This 
evidence is corroborated by other studies which show that ectopic expression of 
SHH in Pancreatic Duct Epithelial Cells (PDECs) drives proliferation in the cells, 
and protects them from apoptosis. Transplantation of the SHH expressing PDEC 
cells in immunocompromised mice can also lead to the formation of PDAC 
precursor lesions. Also, SHH and KRAS expression have a synergistic effect on 
the tumorigenicity of the PDECs when transplanted into immunocompromised 
mice142.  
Non-Canonical GLI signaling: 
The non-canonical model for Hedgehog signaling in pancreatic malignancies 
suggests that GLI transcriptional activity can be driven in the absence of the 
Hedgehog ligand and Smoothened activation during pancreatic tumorigenesis 
(Figure 1.5). This model is supported by the findings which show that expression 
of Hedgehog target genes in the epithelium of PanIN mice is sustained even in the 
absence of Smoothened, the canonical bottleneck for Hedgehog signaling143. In 
this study, the authors also present evidence that GLI1 cooperates with KRAS in 
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vitro to enhance proliferation in human PDAC cell lines, and that GLI1 can be 
regulated by KRAS, and TGF-β in PDAC cells. These findings support a model in 
which GLI transcriptional activity is maintained in PDAC tumor epithelial cells in 
the absence of canonical Hedgehog signal transduction, and is instead regulated 
by oncogenic KRAS. While GLI1 acts downstream of KRAS in PDAC cells, ectopic 
expression of a dominant active allele of Gli2 (Cleg2) in the pancreas has been 
shown to drive formation of undifferentiated tumors, in the absence of upstream 
Hedgehog pathway activation or KRAS mutation139. These undifferentiated tumors 
did not arise through PanIN lesions as is the case in human PDAC formation. In 
contrast, when the Cleg2 allele was expressed in combination with oncogenic 
Kras, it led to the formation of accelerated PanIN lesions. Together, these findings 
highlight a potentially critical role of GLI transcription factors in PDAC, and 
cooperation between GLI and oncogenic KRAS in pancreatic tumorigenesis. 
While the studies described above point to a significant involvement of 
Hedgehog/GLI in pancreatic tumorigenesis, the mechanism of signaling as well as 
the implications of Hedgehog/GLI activity in the epithelial and stromal 
compartments of PDAC tumors are less clear. Recently published data about 
paracrine Hedgehog signaling and the tumor suppressive role of the stroma in 
PDAC are in conflict with an earlier report which indicates that stromal ablation 
may be beneficial in treating tumors. Part of the difference in these findings can be 
attributed to the differences in design of the two experiments. In the 2009 study 
involving treatment of mice bearing PDAC tumors with the Smoothened inhibitor 
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IPI-92639, the authors failed to detect an effect on tumor growth after treatment 
with the Smoothened antagonist alone, however, a statistically significant 
improvement in survival was observed with combined treatment of IPI-926 with 
Gemcitabine. However, as this experiment involved only 3 weeks of treatment, the 
duration of the study may not be sufficient to study long term effects of stromal 
depletion. In the 2014 study involving stromal depletion40, the mice were treated 
for a longer duration using a similar treatment protocol, which led to decreased 
survival in response to combined IPI-926/Gemcitabine compared to treatment with 
IPI-926 alone. These findings are consistent with the results of IPI-926 treatment 
for PDAC in the clinic. Significant improvement in vasculature, as well stromal 
depletion in response to Smoothened inhibition was observed in both the studies. 
This suggests that the difference in survival outcome in response to IPI-926 in the 
two studies may be attributed to the differential effect of short term vs chronic 
Smoothened inhibition and stromal depletion, rather than a difference in the 
underlying mechanism of activity of IPI-926. 
Findings about Smoothened independent non-canonical GLI activity in the PDAC 
epithelium are also in conflict with earlier reports about autocrine Hedgehog 
signaling in PDAC. Although it was shown earlier that treatment with the 
Smoothened antagonist Cyclopamine can lead to decreased survival in human 
PDAC cells in vitro, and in xenograft models in vivo, Cyclopamine is known to have 
non-specific effects at dosages used in this experiment144,145,37, which may imply 
that the effect of the inhibitor on the PDAC cells is Hedgehog/Smoothened 
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independent. Also, the in vivo experiment in this study does not distinguish 
between the effect of Cyclopamine on the stroma vs the epithelium, and therefore 
does not distinguish between autocrine and paracrine Hedgehog signaling. Also, 
while it has been shown in a previous study that Sonic Hedgehog may protect 
pancreatic epithelial cells from apoptosis, and promote survival via autocrine 
mechanisms, and also drive tumorigenicity in mouse models142, this study utilizes 
a gain of function approach in which Sonic Hedgehog is ectopically expressed. 
While Sonic Hedgehog ectopic expression may promote pancreatic tumorigenesis 
via autocrine mechanisms under certain conditions, the available evidence is not 
sufficient to conclude a role for autocrine Hedgehog signaling in PDAC. 
Although published data implicates Hedgehog/GLI activity in pancreatic 
tumorigenesis, a requirement per se for GLI transcriptional activity for tumor 
initiation and progression has not been demonstrated in vivo. In this study, we use 
a mouse model to test the requirement of GLI transcription factors in initiation of 
pancreatic neoplasia, as well as progression to full blown adenocarcinoma. We 
also test the role played by individual GLI transcription factors in pancreatic 
tumorigenesis, and identify a novel oncogenic transcriptional program regulated 
by GLI in pancreatic cancer.  
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Figure 1.1: Initiation and progression of Pancreatic Ductal Adenocarcinoma 
(PDAC) 
Adapted from Bardeesy et al 2002, Morris et al 2010, and Eser et al 2013 30,56,146. 
Oncogenic mutations in KRAS are the initiating event in pancreatic transformation. 
In mouse models, KRAS activation in acinar, ductal, as well as islet cells can lead 
to transformation to a duct-like cell, which in the presence of chronic inflammation 
can give rise to PanIN lesions. PanIN lesions can progress in intensity to full blown 
adenocarcinoma. In human cases, loss of function genetic alterations are acquired 
in tumor suppressors during progression to adenocarcinoma. Downstream 
signaling pathways such as NF-kB, PI3K/AKT, and Hedgehog/GLI are 
misregulated during transformation, and increased desmoplasia and inflammation 
is observed.  
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Figure 1.2: Mammalian Hedgehog Signaling Pathway 
Adapted from Ruel et al 2009147. 
A) In the absence of Hedgehog ligands, Patched1 inhibits Smoothened, and 
Suppressor of Fused (SUFU) sequesters the GLI transcription factors in the 
cytoplasm 
B) When Hedgehog ligands bind to Patched1, Smoothened is activated, and SUFU 
inhibition of Gli transcription factors is relieved, leading to transcriptional activation. 
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Figure 1.3: Paracrine Hedgehog/GLI Signaling in PDAC 
Adapted from Theunissen et al 200934   
Hedgehog ligands are secreted by the pancreatic tumor epithelium in response to 
oncogenic KRAS activation. The ligands inhibit Patched1 on the stromal cells and 
drive downstream pathway activation and GLI transcriptional activity in the stroma 
via Smoothened. Stromal cells may engage in reciprocal signaling with the tumor 
epithelium. 
  
 34 
 
 
Figure 1.4: Autocrine Hedgehog/GLI signaling in PDAC 
Hedgehog ligand is secreted by the pancreatic epithelium, and signals to Patched1 
in the epithelium, which leads to downstream pathway activation via Smoothened, 
and GLI transcriptional upregulation. 
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Figure 1.5: Non-canonical GLI signaling in PDAC 
GLI transcription is activated in the pancreatic tumor epithelium independently of 
Hedgehog/Smoothened by oncogenic KRAS, and drives target gene expression 
in the tumor epithelium.  
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Chapter II: GLI requirement in KRAS induced initiation and progression of 
PDAC  
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Figure Contributions 
Data for this chapter has been published in Rajurkar et al 2012, PNAS148. 
Figure 2.5 was provided by Dr. Wilfredo DeJesus Monge and has been published 
in Rajurkar et al 2012. 
Data for gene expression in mouse BCC, medulloblastoma, and 
rhabdomyosarcoma (Figure 2.9B) was obtained from Mao et al 2006149 
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RESULTS 
GLI transcriptional activity is dispensable for pancreatic development 
To investigate the role of GLI transcriptional activity in pancreatic development, we 
used a Rosa26 knock-in allele of Gli3T (R26-Gli3T), which allows ectopic 
expression of the Gli3T protein from the ubiquitously expressed Rosa26 locus 
following Cre-mediated recombination (Figure 2.1E). Gli3T is a C-terminally 
truncated form of GLI3, which acts as a dominant repressor of GLI transcription150. 
We found that over-expression of Gli3T specifically inhibits GLI1 and GLI2 
dependent gene transcription, but not lymphoid enhancer-binding factor-1 (LEF1) 
or serum-response-factor (SRF) mediated gene transcription in cultured NIH3T3 
cells (Figure 2.2A-C). These results show the specificity and effectiveness of the 
Gli3T allele in blocking Hedgehog/GLI transcriptional activation.  
We crossed R26-Gli3T mice to P48Cre (Ptf1a-Cre) transgenic mice that direct Cre 
recombinase expression to the epithelial lineages of the mouse pancreas151. 
P48Cre;R26-Gli3T mice were born at the expected frequency, and their pancreata 
showed normal parenchymal architecture and cytodifferentiation up to the age of 
12 months, the longest time examined (n = 10) (Figure 2.2E and J). In the R26-
Gli3T allele, a 3XFlag tag and IRES-Venus unit are also inserted at the C-terminus 
of Gli3T to facilitate identification of transgene expression150.  Therefore, we used 
detection of the Flag-tag with immunoblotting (Figure 2.2D), and Venus 
fluorescence on cryosections (Figure 2.2N) to confirm Cre-mediated expression of 
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Gli3T in pancreatic tissue from P48Cre;R26-Gli3T mice. We analyzed the 
expression of the endocrine markers Insulin and Glucagon, and the acinar cell 
marker Amylase, and found no significant differences between Gli3T-expressing, 
and control pancreata (Figure 2.2F, G, H, K, L and M). This data shows that GLI 
inhibition does not affect differentiation of the pancreatic epithelial lineages, and 
suggests that cell-autonomous Hedgehog/GLI activity is largely dispensable for 
the proper development of mouse pancreas.  
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Figure 2.1: Schematic representation of Hedgehog/GLI alleles  
A) SmoM2 is a constitutively active mutant of Smoothened that acts as an 
upstream activator of GLI transcription factors. GLI1, and GLI2 are transcriptional 
activators, and GLI3 is predominantly a transcriptional repressor. (B-E) Gli1, Gli2, 
SmoM2, and Gli3T alleles are knocked into the Rosa26 locus which is ubiquitously 
expressed in mice. Expression is dependent on Cre-mediated recombination. 
Gli3T is a C-terminal truncated version of GLI3 that is capable of inhibiting 
transcription by all the GLI transcription factors. (F) Gli3 floxed allele carries loxP 
sites flanking exon 8 of the endogenous Gli3. Cre-mediated recombination enables 
excision of exon 8 thereby abrogating Gli3 expression.  
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Figure 2.2: GLI activity is dispensable for pancreatic development 
(A–C) Gli3T blocks Gli-dependent transcriptional activity. Gli3T inhibited Gli- 
luciferase reporter activity induced by GLI1 and GLI2 in transfected NIH3T3 cells 
(A). Gli3T does not inhibit TCF4-induced TopFlash reporter activity (B) or serum-
response factor–dependent SRE-luc reporter activity induced by the CDC42 
GTPase (C). Open bars represent control cells; black bars represent Gli3T-
expressing cells. Data shown are expressed as mean ± standard deviation. (D) 
Western blot analysis of Gli3T–Flag expression in pancreatic lysates from 6-
month-old R26-Gli3T and P48Cre;R26-Gli3T mice. (E–N) H&E staining (E and J), 
immunofluorescence staining (red) of Amylase (F and K), Glucagon (G and L), and 
Insulin (H and M), and Venus fluorescence (I and N) in pancreata derived from 12 
month old R26-Gli3T (E–I) and P48Cre;R26-Gli3T (J–N) mice.
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GLI activation does not affect pancreatic development 
To further test the role of individual GLI transcription factors in pancreatic 
development, we also utilized Rosa26 knock-in alleles of Gli1 and Gli2 which act 
as transcriptional activators (Figure 2.1B and C)152,153. In addition, we used a 
conditional knockout allele of the repressor Gli3 (Gli3fl/fl) to specifically delete Gli3 
in the pancreatic epithelium (Figure 2.1 F)154. We bred the R26-Gli1, R26-Gli2, and 
Gli3fl/fl mice with P48Cre mice to generate P48Cre;R26-Gli1, P48Cre;R26-Gli2, 
and P48Cre;Gli3fl/fl mice (N=8). We found that pancreas of these mice had largely 
normal architecture compared to wild type mice at 12 months of age (Figure 2.3A-
D).  
We also tested expression of the endocrine markers Insulin and Glucagon, and 
acinar cell marker Amylase in the pancreas of P48Cre;R26-Gli1 mice using 
immunofluorescence. We found that P48Cre;R26-Gli1 mice had normal 
expression of the markers when compared to the control mice (Figure 2.3 E-K), 
thus indicating that GLI activation does not affect differentiation of the pancreatic 
lineages. This data suggests that cell autonomous GLI1/2 activation or GLI3 
removal does not affect development and differentiation of the pancreas.  
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Figure 2.3: GLI activation does not affect pancreatic development 
(A-D) H&E stained sections of pancreata from 12 month old wild type (A), 
P48Cre;R26-Gli1 (B), P48Cre;R26-Gli2, P48Cre;Gli3fl/fl mice. (E-L) 
Immunofluorescence staining (red) for Amylase (E and I), Insulin (E and J), and 
Glucagon for pancreata from 12 month old R26-Gli1 (E-G) and P48Cre;R26-Gli1 
(I-K) mice, and immunohistochemistry for Ki67 for pancreata from 12 month old 
R26-Gli1 (H), and P48Cre;R26-Gli1 (L) mice. 
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GLI activity is required for KRAS induced PanIN lesions 
We next investigated the specific role for GLI transcription in regulating KRAS 
initiated pancreatic tumor development in vivo. For this purpose, we generated a 
mouse model in which simultaneous activation of KRAS and inhibition of GLI 
transcription was achieved by breeding mice harboring a conditionally activated 
Kras allele (LSL-KrasG12D)155 with P48Cre;R26-Gli3T mice. As expected, Cre-
mediated activation of the LSL-KrasG12D allele in the mouse pancreas resulted in 
the development of slowly progressive pancreatic intraepithelial neoplasia lesions 
(PanINs)54. At 6 months of age, P48Cre;LSL-KrasG12D mice developed early PanIN 
lesions (Figure 2.4A). These lesions showed evidence of epithelial transformation, 
with associated mucin accumulation as detected by Alcian blue staining, and a 
high proliferation index, demonstrated by Ki67 immunohistochemistry (IHC) 
(Figure 2.4E and I). By 12 months of age, the pancreata of the P48Cre;LSL-
KrasG12D mice displayed evidence of advanced lesions, including PanIN2 and 
PanIN3 grade lesions (Figure 2.4C).  
In contrast, inhibition of GLI activity resulted in a dramatic reduction in KRAS driven 
tumorigenesis. P48Cre;LSL-KrasG12D;R26-Gli3T mice (n=15) examined at 6 
months and 12 months of age showed a largely normal parenchymal architecture 
in the pancreas, with little evidence of neoplasia (Figure 2.4B and 2D). There was 
no evidence of epithelial transformation, as assayed by Alcian blue staining, and 
most of the cells in the pancreas were non-proliferating as determined by Ki67 
staining (Figure 2.4F and 2J). There was also no evidence of reactive stroma, 
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which is a hallmark of pancreatic transformation. These findings suggest a critical 
requirement for GLI transcriptional activation in KRAS induced PanIN lesion 
formation in vivo.   
Interestingly, we did detect a few rare PanIN1 lesions in three P48Cre;LSL-
KrasG12D;R26-Gli3T mice (Figure 2.4G and 2H). This observation suggests the 
possibility that the GLI requirement could eventually be overcome, or that the 
lesions that developed failed to express Gli3T. To differentiate between these 
possibilities, we assayed for Gli3T transgene expression in these lesions. Because 
of the high background in detecting the Gli3T C-terminal Flag-tag with 
immunofluorescence staining or IHC, we took advantage of the IRES-Venus unit 
inserted in the R26-Gli3T allele that allows detection of transgene expression by 
Venus fluorescence on cryosections. We found that the lesions from the 
P48Cre;LSL-KrasG12D;R26-Gli3T mice were Venus negative compared to the 
adjacent normal appearing islet and acinar tissues (Figure 2.4G and H), thus 
indicating that the Gli3T transgene was not expressed in these lesions. These 
results suggest that the development of rare lesions in animals bearing the R26-
Gli3T allele is due to inefficient Cre recombination, and the failure to express Gli3T. 
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Figure 2.4: GLI transcriptional activity is required for KRAS induced 
pancreatic neoplasia  
(A–D) Representative H&E stained sections from pancreas of 6 month old (A-B), 
and 12 month old (C-D) P48Cre;LSL-KrasG12D (A and C), and P48Cre;LSL-
KrasG12D;R26-Gli3T (B and D) mice. H&E staining shows widespread advanced 
PanIN formation in P48Cre;LSL-KrasG12D pancreata, but only rare PanIN1 lesions 
were detected in a 12-mo-old and P48Cre;LSL-KrasG12D;R26-Gli3T sections.  (E-
F) Alcian blue stained paraffin sections from 6 month old P48Cre;LSL-KrasG12D(E), 
and P48Cre;LSL-KrasG12D;R26-Gli3T (F) mice. Alcian blue staining indicates 
widespread neoplasms in 12 month old P48Cre;LSL-KrasG12D mice, but no 
evidence of neoplasia in P48Cre;LSL-KrasG12D;R26-Gli3T mice. (G-H) H&E 
staining (G), and Venus fluorescence on a PanIN lesion from a P48Cre;LSL-
KrasG12D;R26-Gli3T mouse. Note robust Venus fluorescence in adjacent acinar 
and endocrine cells indicating expression of Gli3T, but lack of fluorescence within 
the lesion. The boundary of the lesions from the adjacent slides is delineated by 
dashed black (G) and white (H) lines. (I-J) Ki76 immunohistochemistry on sections 
from pancreas of 6 month old P48Cre;LSL-KrasG12D (I), and P48Cre;LSL-
KrasG12D;R26-Gli3T (J) mice. High number of proliferative cells are seen in 
P48Cre;LSL-KrasG12D but not P48Cre;LSL-KrasG12D;R26-Gli3T mouse pancreas. 
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GLI activation is required for Kras-dependent PDAC formation 
Our data suggests that GLI transcriptional activity is required for KRAS initiated 
formation of precursor PanIN lesions. To test whether GLI activity is required for 
progression of these lesions to full blown adenocarcinoma, we generated 
compound mice bearing a single conditional knockout Trp53 allele156, in addition 
to the LSL-KrasG12D, R26-Gli3T, and P48Cre alleles. Mice negative for the R26-
Gli3T allele rapidly developed pancreatic adenocarcinoma, with a median latency 
of 111 days (range 85-164 days) (Figure 2.5A). These tumors were predominantly 
moderate to poorly-differentiated ductal adenocarcinomas that were frequently 
invasive and metastatic, with dissemination to lymph nodes, the adjacent intestine, 
liver, peritoneal cavity and lungs (Figure 2.5B, panels i-v). By contrast, mice 
bearing the R26-Gli3T allele developed carcinomas with a longer latency, with a 
median age of 193 days (range 115-270 days) (Figure 2.5A). In spite of delayed 
kinetics, the tumors that developed in the R26-Gli3T positive animals were 
histologically indistinguishable from those in R26-Gli3T negative mice, and were 
also commonly metastatic (Figure 2.5B, panels vi-ix).  
The eventual formation of pancreatic tumors in animals bearing the R26-Gli3T 
allele again raises the question whether the tumors that developed failed to 
express Gli3T, or whether Trp53 deletion obviates the need for GLI activity, as 
suggested by a previous study157. Thus, we assayed for the presence of the Gli3T 
protein in lysates from tumors, and cell lines derived from these tumors, by 
immunoblotting with an anti-Flag antibody. While Gli3T protein could be readily 
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detected in 293T cells transfected with a Gli3T expression construct (and pancreas 
tissue from P48Cre;R26-Gli3T mice, see Figure 2.2), Gli3T could not be detected 
in any of the tumor (Figure 2.5C, top panel) or cell line (Figure 2.5C, lower panel) 
lysates. To determine whether these tumors were derived from cells that failed to 
undergo recombination, we analyzed DNA extracted from tumors and cell lines 
with PCR primers that differentiate between unrecombined and recombined R26-
Gli3T alleles. The unrecombined allele was readily detected in all samples isolated 
from mice carrying the R26-Gli3T allele, whereas only one tumor sample tested 
positive for the presence of the recombined allele (Figure 2.5D). Interestingly, a 
cell line derived from the tumor that tested positive for recombination was negative 
for the presence of the recombined R26-Gli3T allele, suggesting that the cells in 
the tumor carrying the recombined allele represented a minority of the sample, or 
were normal epithelial cells entrapped within the mass of the tumor. Collectively, 
our data demonstrate that GLI transcriptional activity is required for pancreatic 
adenocarcinoma formation in vivo. 
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Figure 2.5: GLI inhibition prolongs survival in a mouse model of PDAC 
(A) Kaplan–Meier survival curve for P48Cre;LSL-
KrasG12D;Trp53flox/wt mice, P48Cre;LSL-KrasG12D;Trp53flox/wt;R26-Gli3T mice, 
and P48Cre and LSL-KrasG12D negative littermate controls. P < 0.001 for 
comparison between R26-Gli3T–positive and –negative animals. (B) 
Representative H&E-stained histological sections from lesions arising 
in P48Cre;LSL-KrasG12D;Trp53flox/wt (i–v) and P48Cre;LSL-
KrasG12D;Trp53flox/wt;R26-Gli3T(vi–ix) mice. PanIN lesions (i), glandular PDAC (ii), 
undifferentiated carcinoma (iii), lymph node metastasis (iv), and liver metastasis 
(v) were identified in P48Cre;LSL-KrasG12D;Trp53flox/wt mice. Glandular PDAC (vi), 
undifferentiated carcinoma (vii), liver metastasis (viii), and intestinal invasion (ix) 
were observed in P48Cre;LSL-KrasG12D;Trp53flox/wt;R26-Gli3T mice. (C) 
Immunoblotting for Gli3T protein (using an anti-Flag antibody) in lysates from R26-
Gli3T positive (+) and –negative (−) tumors (Upper) and cell lines derived from 
these tumors (Lower). (D) PCR of genomic DNA to detect the recombination status 
of the R26-Gli3T allele in R26-Gli3T positive tumor samples. Amplification of the 
native Rosa26 locus was used as a control.  
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GLI, but not Smoothened activation accelerates KRAS initiated pancreatic 
tumorigenesis 
Prior work has suggested that KRAS regulates Gli1 expression in PDAC cells, and 
GLI1 activity is critical for PDAC cell survival and transformation in vitro143. Reports 
have also suggested that GLI2 ectopic expression in the absence of oncogenic 
KRAS can give rise to undifferentiated tumors in the pancreas139. In order to test 
whether GLI transcriptional activity can cooperate with KRAS in driving 
tumorigenesis, we used the Rosa26 knock-in alleles of Gli1 and Gli2, and the Gli3 
floxed allele to generate P48Cre;LSL-KrasG12D;R26-Gli1, P48Cre;LSL-
KrasG12D;R26-Gli2, and P48Cre;LSL-KrasG12D;R26-Gli3fl/fl mice.  
Previous data has suggested that conditional knockout of the GLI upstream 
activator Smoothened in the context of oncogenic KRAS does not affect pancreatic 
tumorigenesis143. In order to test whether activation of Smoothened can cooperate 
with oncogenic KRAS, we also used a previously described oncogenic allele of 
Smoothened (SmoM2) that was knocked in to the Rosa26 locus (R26-SmoM2)149. 
P48Cre;LSL-KrasG12D;R26-Gli1, P48Cre;LSL-KrasG12D;R26-Gli2, P48Cre;LSL-
KrasG12D;R26-SmoM2, and P48Cre;LSL-KrasG12D;R26-Gli3fl/fl mice were 
generated and monitored for over 12 months. We found that P48Cre;LSL-
KrasG12D;R26-Gli1, and P48Cre;LSL-KrasG12D;R26-Gli2 showed dramatically 
accelerated tumorigenesis compared to P48Cre;LSL-KrasG12D mice. At 2 months 
age, when normal architecture is preserved in most of the pancreas of 
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P48Cre;LSL-KrasG12D mice, with normal islets, acini, and ducts making up majority 
of the pancreas, and only a small number of low grade PanIN1 lesions (Figure 
2.6A). In contrast to this, P48Cre;LSL-KrasG12D;R26-Gli1, and P48Cre;LSL-
KrasG12D;R26-Gli2 mice presented with high grade PanIN3 lesions (Figure 2.6B-
C) that showed signs of severe nuclear atypia, and luminal invasion. Normal 
pancreatic architecture was almost completely destroyed in these mice.  
While KRAS activation in the pancreas was sufficient to initiate transformation, the 
P48Cre;LSL-KrasG12D mice did not show significantly accelerated mortality 
compared to wild type mice, and most P48Cre;LSL-KrasG12D mice lived over 12 
months. However, we found that P48Cre;LSL-KrasG12D;R26-Gli1, and 
P48Cre;LSL-KrasG12D;R26-Gli2 had a dramatically reduced survival, with most 
mice not living past 2 months age (Figure 2.6F).  This data suggests that GLI1 and 
GLI2 can cooperate with oncogenic KRAS to accelerate pancreatic tumorigenesis. 
In contrast to the GLI1/2 activation, we found that the rate of pancreatic 
transformation in P48Cre;LSL-KrasG12D;R26-SmoM2, and P48Cre;LSL-
KrasG12D;R26-Gli3fl/fl was not significantly different from P48Cre;LSL-KrasG12D 
mice. SmoM2 ectopic expression, and Gli3 deletion did not affect survival of the 
mice, with most mice living past 12 months (Figure 2.6D-F). Our findings suggest 
that while GLI1, or GLI2 ectopic expression can dramatically accelerate pancreatic 
tumorigenesis in cooperation with KRAS, oncogenic activation of Smoothened, 
and deletion of Gli3 does not affect pancreatic tumorigenesis.  
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Molecular analysis of the P48Cre;LSL-KrasG12D;R26-Gli1 advanced lesions 
revealed that cell proliferation, as measured by Ki67 staining, was significantly 
increased compared to the in the P48Cre;LSL-KrasG12D mice (Figure 2.7A-C). 
Consistent with a previous report58, we also detected senescence-associated β-
galactosidase expression in early PanIN lesions from two-month-old P48Cre;LSL-
KrasG12D mice (Fig. 2.7D), while high-grade PanIN lesions from age-matched 
P48Cre;LSL-KrasG12D;R26-Gli1 mice did not exhibit detectable senescence-
associated β-galactosidase staining (Figure 2.7E), suggesting escape from KRAS 
induced growth arrest/senescence. Immunofluorescence for Cytokeratin-8 
conducted on P48Cre;LSL-KrasG12D;R26-Gli1 confirmed the epithelial nature of the 
PanIN lesions, and we also found evidence of a high degree of desmoplasia in the 
pancreas as evidenced by Smooth Muscle Actin staining (Fig. 2.7I).  
In spite of dramatically accelerated PanIN lesion formation and mortality, we did 
not detect invasive PDAC in the P48Cre;LSL-KrasG12D;R26-Gli1, and P48Cre;LSL-
KrasG12D;R26-Gli2 mice, and metastasis was not observed in any of the mice we 
examined. Interestingly, we detected large multilocular cystic lesions resembling 
mucinous cystic neoplasms (Figure 2.7G) in two of the P48Cre;LSL-KrasG12D;R26-
Gli1 mice, in addition to the PanIN lesions we described above. The cysts from the 
P48Cre;LSL-KrasG12D;R26-Gli1 mice were as large as 2 cm in diameter and lined 
by columnar epithelial cells, where abundant mucin production was demonstrated 
by reaction with Alcian blue (Figure 2.7H).  Together, our results suggest that GLI 
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activation is not sufficient to initiate PDAC, but synergizes with KRAS to promote 
pancreatic tumor formation in vivo.   
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Figure 2.6: Activation of GLI accelerates KRAS induced pancreatic 
tumorigenesis 
(A-C) H&E staining on pancreas sections of 2 month old P48Cre;LSL-KrasG12D (A), 
P48Cre;LSL-KrasG12D;R26-Gli1 (B), and P48Cre;LSL-KrasG12D;R26-Gli2 (C) mice. 
Mice with GLI1 or GLI2 ectopic expression in combination with KRASG12D show 
formation of advanced PanIN lesions whereas mice with KRASG12D show rare 
instances of early PanIN lesions. (D-E) H&E staining on pancreas sections of 6 
month old P48Cre;LSL-KrasG12D (D), and H&E staining on pancreas sections of 2 
month old P48Cre;LSL-KrasG12D;Gli3fl/fl (E) mice. Abrogation of GLI3 expression 
does not significantly affect PanIN lesion formation. (F) Kaplan-meier survival 
curve for P48Cre;LSL-KrasG12D, P48Cre;LSL-KrasG12D;R26-Gli1, P48Cre;LSL-
KrasG12D;R26-Gli2, P48Cre;LSL-KrasG12D;R26-SmoM2, and P48Cre;LSL-
KrasG12D;R26-Gli3fl/fl mice. GLI1/2 activation leads to a dramatic decrease in 
survival, while ectopic expression of SmoM2 and deletion of Gli3 does not affect 
survival. 
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Figure 2.7: GLI1 drives cell proliferation, evasion of senescence and 
desmoplasia in pancreatic neoplasms 
(A-C) Immunohistochemistry for Ki67 on pancreata sections from 2 month old 
P48Cre;LSL-KrasG12D (A), and P48Cre;LSL-KrasG12D;R26-Gli1 (B) mice. 
Quantification of Ki67 positive nuclei shows significantly higher proliferation in 
P48Cre;LSL-KrasG12D;R26-Gli1 mouse PanIN lesions (C). (D-E) β-Galactosidase 
staining for senescence on sections from 12 month old P48Cre;LSL-KrasG12D (D), 
and P48Cre;LSL-KrasG12D;R26-Gli1 (E) mice. Quantification of β-Galactosidase 
positive cells shows significantly higher senescence in P48Cre;LSL-KrasG12D;R26-
Gli1 mouse PanIN lesions (F). (G) H&E staining of pancreatic cystic lesions from 
a 1 month old P48Cre;LSL-KrasG12D;R26-Gli1 mouse. (H) Alcian blue staining 
revealing abundant mucin production in epithelial cells in the cysts. (I) 
Immunofluorescence for Cytokeratine 8 (red), and Smooth muscle actin (green) 
on sections from a P48Cre;LSL-KrasG12D;R26-Gli1  mouse showing strong 
desmoplastic reaction. 
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A GLI dependent transcriptional program in PDAC cells 
The results from our loss-of-function and gain-of-function genetic analyses 
underscore the functional importance of cell autonomous GLI activation in 
pancreatic epithelial transformation. However, the GLI mediated transcriptional 
program in pancreatic cancer remains largely unexplored.  
Panc1 and MiaPaCa2 are human PDAC cell lines that contain activating mutations 
in KRAS, and are a commonly used model to study pancreatic cancer143. We found 
that inhibition of GLI activity in these cell lines by ectopic expression of Gli3T led 
to a significant decrease in cell proliferation, increase in apoptosis, and decrease 
in tumorigenicty measured by soft agar colony formation (Figure 2.8 A-C). 
Knockdown of GLI1 in these cells using two different shRNAs also led to a dramatic 
decrease in cell proliferation, increase in apoptosis, and decrease in tumorigenicity 
(Figure 2.8D-F), and these findings could also be replicated by inhibition of GLI 
activity using a small molecule inhibitor of GLI, Gant61158 (Figure 2.8G-I). This data 
highlights the importance of GLI transcriptional activity in maintaining the 
oncogenic properties of the KRAS mutant human PDAC cell lines. We used the 
Panc-1 cell line as a model to further analyze the transcriptional program regulated 
by GLI in PDAC. 
To identify GLI dependent downstream target genes, we performed gene 
expression profiling on Gli3T expressing Panc-1 cells, and vector controls. We 
transfected Panc-1 cells with a Gli3T-IRES-nuclear GFP expression construct, and 
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24 hours post-transfection we isolated GFP-positive cells by flow cytometry 
(FACS), and performed expression profiling using Affymetrix chips. As expected, 
we detected upregulation of GLI3. that likely reflects the expression of the ectopic 
Gli3T transgene. We identified 265 genes that were significantly downregulated by 
Gli3T (refer to Rajurkar et al 2012 for data set148); among them, PTCH1 and 
FOXA2 are known transcriptional targets of the Hedgehog/GLI pathway (Figure 
2.9A). Interestingly, we found that the majority of the genes identified in our array 
were not known GLI target genes, and were not previously associated with 
Hedgehog/GLI signaling. When we compared the genes identified in our screen to 
the Hedgehog target genes expressed in Hh induced BCC, medulloblastoma, and 
rhabdomyosarcoma, we found only few overlapping genes (Figure 2.9B), thus 
indicating that Gli regulates a unique transcriptional program in the context of 
pancreatic cancer.  
We identified several genes involved in regulating RAS intracellular signal 
transduction, including SOS2 (RasGEF), RASA1 (RasGAP), RIN2 and RASSF4/5 
(Figure 2.9A), suggesting possible feedback regulation of Kras signaling in cancer 
cells influenced by GLI activity. The PI3K/AKT and MEK/Erk pathways are KRAS 
stimulated signaling pathways that have been implicated in tumorigenesis159. In 
our transcriptional profiling, we found that two subunits of PI3K, PIK3R1 and 
PIK3C2B, were among the genes whose expression was significantly 
downregulated by Gli3T (Figure 2.9A), indicating a possible interaction between 
GLI and PI3K/AKT signaling. We also detected an enrichment of genes associated 
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with the NF-B pathway, including IKBKE (IKK), TRAF1, TRAF3IP2 and NFKBIE, 
indicating that GLI may play a role in regulating the NF-кB pathway in PDAC 
(Figure 2.9A). Together, these findings point to a potential previously unidentified 
role played by GLI in regulating the KRAS, PI3K/AKT and NF-кB pathways in 
PDAC. 
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Figure 2.8: GLI transcriptional activity is required for human PDAC cell 
survival 
Significant decrease in cell proliferation is seen as measured by MTT assay in 
response to inhibition by Gli3T (A), shRNA mediated knockdown of GLI1 (D), and 
treatment with small molecule GLI inhibitor Gant61 (G) in Panc-1 (black bars), and 
MiaPaca2 (grey bars) cells. Apoptosis levels are significantly increased in 
response to Gli3T repression (B), shRNA knockdown of GLI1 (E), and treatment 
with Gant61 (H) in Panc-1 and MiaPaca2 cells as measured by 
immunofluorescence for cleaved-Caspase-3.  Tumorigenicity of Panc-1 and 
MiaPaca2 cells is significantly decreased in response to Gli3T repression (C), GLI1 
knockdown (F), and Gant61 treatment (I). Error bars represent standard deviation. 
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Figure 2.9: A GLI mediated transcriptional program in PDAC 
(A) Heat map illustrating mRNA expression of selected genes in Gli3T-expressing 
and control Panc1 cells. Red, high expression; green, low expression. (B) 
Schematic showing number of Gli regulated genes in PDAC, and BCC, 
medulloblastoma (MB) and rhabdomyosarcoma (RMS). 
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GLI regulates AKT activation in PDAC: 
As discussed previously, the PI3K/AKT pathway is an important effector of KRAS 
in pancreatic transformation. While KRAS is known to directly regulate PI3K 
activity at the cell membrane, our findings implicate GLI as a potential 
transcriptional regulator of the PI3K pathway. In order to further test the role of GLI 
in PI3K/AKT signaling, we inhibited GLI transcriptional activity in Panc-1 cells using 
the Gli3T repressor. We found that GLI inhibition led to a significant decrease in 
AKT phosphorylation at Serine-473. In contrast, we did not detect any significant 
difference in phosphorylation of ERK, which is another important oncogenic 
effector of KRAS that acts downstream of RAF/MEK in PDAC (Figure 2.10A). Also, 
we found that inhibition of GLI activity using the small molecule inhibitor Gant61 
led to a dosage dependent decrease in AKT phosphorylation at Serine-473 (Figure 
2.10B). We decided to further explore the phosphorylation status of both AKT and 
ERK in vivo in P48Cre;LSL-KrasG12D and P48Cre;LSL-KrasG12D;R26-Gli1 mouse 
pancreas. Immunohistochemical staining revealed that while AKT phosphorylation 
at Serine-473 was markedly upregulated in the PanIN lesions of P48Cre;LSL-
KrasG12D;R26-Gli1 mice compared to P48Cre;LSL-KrasG12D mice (Figure 2.10 C-
D), there was no significant difference in the phosphorylation levels of ERK (Figure 
2.10 E-F). Our data suggests that GLI plays a role in regulating the PI3K/AKT 
pathway in pancreatic transformation. These findings also point to an additional 
layer of complexity in KRAS regulation of PI3K/AKT signaling. 
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Figure 2.10: GLI mediates AKT phosphorylation in PDAC 
(A) Immunoblot analysis of levels of AKT phosphorylation (p-AKT S473), total AKT, 
ERK phosphorylation (p-ERK), and total ERK, in isolated Gli3T-expressing and 
control Panc1 cells. (B) Immunoblot showing levels of phospho-AKT and total AKT 
in response to varying doses of Gant61 48 hours after treatment with inhibitor. (C-
F) IHC for p-AKT (C and D) and p-ERK (E and F) in PanIN from 2 month 
old P48Cre;LSL-KrasG12D (C and E) and P48Cre;LSL-KrasG12D;R26-Gli1 (D and F) 
mice. 
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GLI mediated regulation of and NF-B activity in PDAC  
As our gene expression profiling data suggested a possible regulation of the NF-
кB pathway by GLI, we further explored the relationship between NF-кB and GLI 
signaling using human PDAC cells, and in vivo. We first examined whether NF-B 
transcriptional activity is regulated by GLI. Panc-1 cells expressing Gli3T exhibited 
a significantly lower level of NF-B activity compared to cells expressing a control 
plasmid, as assayed by measuring the activity of a synthetic NF-B luciferase 
reporter gene (Figure 2.11A). Next we tested whether NF-кB target gene 
expression is regulated by GLI in PDAC. When treated with Gli3T, NF-кB target 
gene expression was significantly downregulated in Panc-1 cells as measured by 
quantitative RT-PCR (Figure 2.11B), suggesting regulation of NF-кB activity by 
GLI. In order to test regulation of NF-кB by GLI in vivo, we conducted 
immunohistochemical staining for RELA (p65) on pancreata of 2 month old 
P48Cre;LSL-KrasG12D and P48Cre;LSL-KrasG12D;R26-Gli1 mice, as well as human 
PDAC samples. As described previously, p65 is a member of the NF-B family, 
and nuclear accumulation of p65 indicates activation of the classical NF-B 
pathway. We found that, compared to those in P48Cre;LSL-KrasG12D mice, 
epithelial cells in P48Cre;LSL-KrasG12D;R26-Gli1 mice exhibited significantly 
higher levels of p65 in the nucleus (Figure 2.11C-D). The high levels of nuclear 
p65 were comparable to the p65 nuclear translocation in the human PDAC 
samples. In summary, these observations demonstrate regulation of NF-B 
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signaling by GLI proteins in PDAC cells, and highlight a potential mechanism of 
regulation of NF-кB activity by oncogenic KRAS in PDAC formation. 
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Figure 2.11: GLI regulates NF-кB signaling in PDAC 
(A) Relative expression of a p65 (RELA) luciferase reporter in Panc-1 cells 
expressing Gli3T, and a control vector. Significant decrease in p65 luciferase 
activity is seen in response to Gli3T mediated repression. (B) Relative NF-кB target 
gene expression normalized to GAPDH in control, and Gli3T expressing Panc-1 
cells. Significant decrease in NF-кB target gene expression is seen in response to 
Gli3T mediated repression. Error bars represent standard deviation. (C-E) 
Immunohistochemistry for p65 in 2 month old P48Cre;LSL-KrasG12D (C), 
P48Cre;LSL-KrasG12D;R26-Gli1 (D) mouse pancreas sections, and a section of 
human PDAC sample (E). High levels of nuclear p65 indicating NF-кB pathway 
activation are seen in P48Cre;LSL-KrasG12D;R26-Gli1 sections and human PDAC 
samples, but not in P48Cre;LSL-KrasG12D mouse pancreas. 
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MATERIALS AND METHODS 
Mouse strains 
P48Cre, LSL-KrasG12D, Trp53flox, R26-Gli3T, Rosa-26Gli1, Rosa26-Gli2, Rosa26-
SmoM2, and Gli3fl/fl mice have been described before54,160,150,161,154. P48Cre;LSL-
KrasG12D;R26-Gli3T, P48Cre;LSL-KrasG12D;R26-Gli1, P48Cre;LSL-KrasG12D;R26-
Gli2, P48Cre;LSL-KrasG12D; and P48Cre;LSL-KrasG12D;R26-SmoM2 were 
obtained by interbreeding P48Cre mice with LSL-KrasG12D;R26-Gli3T, LSL-
KrasG12D;R26-Gli1, LSL-KrasG12D;R26-Gli2, and LSL-KrasG12D;R26-SmoM2 mice 
respectively. P48Cre;LSL-KrasG12D; Gli3fl/fl mice were obtained by crossing P48Cre 
mice to LSL-KrasG12D; Gli3fl/fl mice. Offspring from the cross of LSL-KrasG12D;R26-
Gli3T  to P48cre;Trp53flox/flox mice were followed longitudinally for tumor 
development for 270 days. All mouse experiments were performed according to 
the guidelines of IACUC at University of Massachusetts Medical School.  
Tissue collection and histology  
Upon euthanasia, primary pancreatic tissues and metastatic lesions were 
separated in pieces and fixed in 4% (wt/vol) paraformaldehyde. For paraffin 
sections, tissues were dehydrated, embedded in paraffin blocks, and cut at a 
thickness of 6 μm. For frozen sections, tissues were dehydrated in 30% (wt/vol) 
sucrose and embedded in Optimal Cutting Temperature compound (OCT; Sakura 
Finetek), and sections were cut at a thickness of 12 μm. For RNA and protein 
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analysis, tissues were flash frozen in liquid nitrogen. Tissue sections (6 μm) were 
stained with H&E using standard reagents and protocols. 
Generation of cell lines from PDAC tumors  
Pancreatic tumors were dissected and minced in cold DMEM containing 10% 
(vol/vol) FBS. The tumor tissue was then plated in a 10-cm tissue culture dish and 
allowed to adhere for 2 days. Media was then changed and tumor pieces removed. 
The epithelial character of the isolated cells was confirmed by staining for pancreas 
epithelial markers such as cytokeratins 8 and 19. 
Immunohistochemistry, immunofluorescence and immunoblotting  
For immunohistochemistry, high-temperature antigen retrieval was conducted in 
Sodium Citrate solution (pH 6.0) on paraffin sections for 30 minutes. Sections were 
blocked in a buffer containing 5% (wt/vol) BSA and 0.1% (vol/vol) Triton X-100 in 
PBS and then were incubated overnight at 4 °C in primary antibodies diluted in 
blocking buffer. Primary antibodies used were: Ki67 (1:500, Abcam), phospho-AKT 
S473 (1:50, Cell Signaling), phospho-ERK (1:500, Cell Signaling), and p65 (1:50, 
Santa Cruz). Signal detection was accomplished with biotinylated secondary 
antibodies in the Vectastain ABC kit (Vector Labs).  
For immunofluorescence, OCT sections were washed with PBS and incubated in 
blocking buffer containing 5% (vol/vol) sheep serum, 1% (vol/vol) FBS, and 0.1% 
(vol/vol) Triton X-100 in PBS. Sections then were incubated overnight at 4 °C in 
primary antibodies diluted in blocking buffer. Primary antibodies used were 
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Glucagon (1:3,000; gift of Andrew Leiter, University of Massachusetts Medical 
School, Worcester, MA); Amylase (1:800; Sigma); Insulin (1:100; Abcam); smooth 
muscle actin (1:500; Sigma); and cytokeratin-8 (1:100; Developmental Studies 
Hybridoma Bank). Alexa Fluor fluorescent conjugated secondary antibodies 
(Invitrogen) were used for detection at a concentration of 1:500 diluted in blocking 
buffer. Slides then were mounted in mounting medium containing DAPI.  
For immunoblotting, primary antibodies used were: FlagM2-HRP (1:1000, Sigma), 
β-Actin (1:1000, Sigma), phospho-AKT S473 (1:1000, Cell Signalling), phospho-
ERK (1:1000, Cell Signaling), total AKT, (1:1000, Cell Signaling), total ERK 
(1:1000, Cell Signaling). HRP conjugated secondary antibodies used for detection 
were obtained from Jackson Laboratories. 
Alcian blue staining and senescence-associated β-galactosidase staining  
For Alcian blue staining, paraffin sections were hydrated and stained for 30 
minutes at room temperature using Alcian blue reagent (IHC World). Sections were 
counterstained with Nuclear Fast Red. For senescence-associated β-
Galactosidase staining, frozen sections were washed in PBS and stained overnight 
using Senescence β-Galactosidase staining solution (Cell Signaling Technology). 
Sections were counterstained using eosin. 
Cell proliferation, apoptosis and soft-agar assays  
Gli3T-expressing GFP-positive Panc1 or MiaPaCa2 cells were isolated 24 h after 
transfection using flow cytometry. For shRNA knockdown, Panc-1 or MiaPaca2 
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cells were infected with pLKO-based lentiviruses expressing shRNAs and were 
selected for 4 days using puromycin. For Gant61 inhibition, Panc-1 or MiaPaca-2 
cells were treated with varying doses of Gant61 dissolved in DMSO. Cell 
proliferation assays were performed in triplicate. 
For the MTT-based cell-proliferation assay, the cells were seeded at a density of 
3,000 cells per well in a 96-well plate, treated with 5 mg/mL MTT 5 days after 
seeding, and lysed in DMSO 4 hours later. Absorbance was measured at 595 nm. 
The assay was performed in triplicate. 
For the apoptosis assay, cells were plated in chamber slides after cell sorting, drug 
selection, or Gant61 treatment. Cells were fixed in 4% paraformaldehyde. 
Immunostaining with a polyclonal antibody against cleaved caspase-3 (1:400; Cell 
Signaling) was used as a marker for apoptosis. Apoptotic cells were counted in 
three wells, and relative apoptosis was measured by comparing the number of 
apoptotic cells with the control sample. Standard deviation was used to calculate 
error bars. 
For the anchorage-independent growth assay using soft-agar, cells were seeded 
at a density of 6,000 cells per well in a six-well plate of 0.3% agarose in DMEM 
containing 10% (vol/vol) FBS. Colonies from 12 fields of view were counted 14 
days later. Assays were performed in triplicate. 
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Luciferase reporter analysis  
Cells were co-transfected with luciferase reporter constructs, GliBS-Luc (gift of Dr. 
H. Kondoh, Osaka University), TOPflash (Addgene), SRE-luc (gift of Dr. D. Wu, 
Yale University), NF-κB-Luc (gift of Dr. F. Chan, UMMS), and expression vectors 
for Renila luciferase, Gli3T, Gli1, Gli2, Lef1 and CDC42. Luciferase assays were 
conducted 48 hours after transfection using the dual-luciferase reporter kit 
(Promega). 
Detection of recombination at the R26-Gli3T locus  
Polymerase chain reaction was performed on isolated genomic DNA using the 
primer pair (Forward: 5’- GTAGTCCAGGGTTTCCTTGATG-3’, Reverse: 5’-
TGCTACTTCCATTTGTCACGTC-3’) for detection of the unrecombined R26-Gli3T 
allele, and (Forward: 5’-GTAGTCCAGGGTTTCCTTGATG-3’, Reverse: 5’-
GGACTTTCATCCTCATTGGAAG-3’) for detection of the recombined allele. 
Primers to the native Rosa26 locus were used as a control (Forward: 5’-
GGAGCGGGAGAAATGGATATG-3’, Reverse: 5’- 
AAAGTCGCTCTGAGTTGTTAT-3’). 
Quantitative RT-PCR   
cDNA synthesis was conducted using Invitrogen SuperScript II kit. Primers used 
for qRT-PCR were human GAPDH (forward: 5′-ATGGGGAAGGTGAAGGTCG-3′; 
reverse: 5′-GGGGTCATTGATGGCAACAATA-3′); mouse Gapdh (forward: 5′-
AGGCCGGTGCTGAGTATGTC-3′; reverse: 5′-TGCCTGCTTCACCACCTTCT-3′); 
β-actin (forward: 5′-TGACAGGATGCAGAAGGAGA-3′; reverse: 5′-
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CTGGAAGGTGGACAGTGAGG-3′); human GLI1 (forward: 5′-
CCAGCGCCCAGACAGAG-3′; reverse:5′-GGCTCGCCATAGCTACTGAT-3′); 
mouse Gli1 (forward: 5′-GTCGGAAGTCCTATTCACGC-3′; reverse: 5′-
CAGTCTGCTCTCTTCCCTGC-3′); human PTCH1 (forward: 5′-
CCACAGAAGCGCTCCTACA-3′; reverse 5′-CTGTAATTTCGCCCCTTCC-3′); 
mouse Ptc1 (forward: 5′-AACAAAAATTCAACCAAACCTC-3′; reverse: 5′-
TGTCTTCATTCCAGTTGATGTG-3′); human IL1A (forward: 
ATCATGTAAGCTATGGCCCACT; reverse: CCTTCCCGTTGGTTGCTACTA), 
mouse Il1a (forward: 5’- TCTATGATGCAAGCTATGGCTCA-3’; reverse: 5’- 
CGGCTCTCCTTGAAGGTGA-3’); human TNFA (forward: 
CCTCTCTCTAATCAGCCCTCTG; reverse: GAGGACCTGGGAGTAGATGAG), 
mouse tnf (forward: 5’- CAGGCGGTGCCTATGTCTC-3’; reverse: 5’- 
CGATCACCCCGAAGTTCAGTAG-3’); human BCL2L1 (forward: 
CTGCTGCATTGTTCCCATAG-3’; reverse: 5’-TTCAGTGACCTGACATCCCA-3’), 
mouse Bcl2l1 (forward: 5’- ACATCCCAGCTTCACATAACCC-3’; reverse: 5’- 
CCATCCCGAAAGAGTTCATTCAC-3’); human BCL2 (forward: 5’-
ATGTGTGTGGAGAGCGTCAA-3’; reverse: 5’-CGTACAGTTCCACAAAGGCA-
3’); and mouse Bcl2 (forward: 5’-GCTACCGTCGTGACTTCGC-3’; reverse: 5’- 
CCCCACCGAACTCAAAGAAGG-3’).  All qPCR assays were conducted in 
triplicate. 
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shRNA mediated knockdown 
Panc1 or MiaPaCa2 cells were infected with pLKO-based lentiviruses encoding 
shRNAs targeting human Gli1 (shGLI1#1: CATCCATCACAGATCGCATTT; 
shGLI1#2: GCTCAGCTTGTGTGTAATTAT). Infected cells were selected in 5 
μg/mL puromycin for 4 days.  
Affymetrix gene chip analysis 
Panc1 cells were transfected with a GFP-expressing vector carrying Gli3T (pCIG-
Gli3T) or a GFP-expressing empty vector (pCIG). GFP-positive cells were isolated 
24 h after transfection using flow cytometry. RNA was isolated, labeled, and 
hybridized to mouse GeneST1.0 chips (Affymetrix) according to Affymetrix 
protocols. Three independent biological samples were used for chip analysis. 
Statistical analyses were performed using R, a system for statistical computation 
and graphics (http://www.r-project.org). Genes with adjusted P value <0.05 and 
absolute fold change ≥1.5 were considered potential targets for further 
investigation. 
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Chapter III: IKBKE signaling in pancreatic neoplasia  
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Figure Contributions 
Data for Figure 3.6B was contributed by Dr. Martin Fernandez-Zapico of Mayo 
Clinic, Rochester, MN 
Results 
IKBKE is a regulated by GLI in pancreatic cancer, and is required for 
transformation 
In our gene expression analysis in human PDAC cells, we identified a number of 
genes that were regulated in a GLI dependent manner that were previously not 
associated with Hedgehog/GLI signaling. The IкB Kinase Epsilon (IKBKE/IKKε) 
was a candidate GLI target gene identified in our screen. IKBKE is an atypical IкB 
kinase that is known to play a role in regulation of the NF-кB pathway118. We found 
that inhibition of GLI using the dominant-negative repressor Gli3T led to a 
significant decrease in IKBKE mRNA and protein levels in Panc-1 cells (Figure 
3.1A and D). Similarly, shRNA mediated knockdown using two different shRNAs 
targeting GLI1, and treatment with a small molecule inhibitor of GLI (Gant61) led 
to a significant decrease in IKBKE mRNA expression levels in Panc-1 cells, 
suggesting that IKBKE expression is regulated by GLI (Figure 3.1B-C). In our in 
vivo model, we found that IKBKE protein levels were markedly upregulated in 
PanIN lesions in P48Cre;LSL-KrasG12D;R26-Gli1 mice compared to P48Cre;LSL-
KrasG12D mice, as assayed by immunohistochemical staining (Figure 3.1E-F). 
These findings implicate IKBKE as a novel GLI target gene in PDAC.  
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Because of its role in transformation of breast cancer cells162, we hypothesized 
that IKBKE may also promote tumorigenesis in the pancreas. We utilized two 
different shRNAs targeting IKBKE and treated two different human PDAC cell lines 
Panc-1 and MiaPaca2 with these shRNAs to achieve significant IKBKE knockdown 
(Figure 3.1G, and 3.2A). In response to IKBKE knockdown, we detected a 
significant decrease in cell proliferation as detected by MTT assay in both Panc-1 
(Figure 3.1H), and MiaPaca2 cells (Figure 3.2B), and this decrease was partially 
rescued by the expression of a non-targetable mouse IKBKE (mIKBKE) construct. 
The mIKBKE construct carried a c-terminal myc-tag to enable detection of the 
protein (Figure 3.1K, and 3.2E). A considerable increase in the level of apoptotic 
cells, measured by cleaved-Caspase-3 immunofluorescence, was also detected in 
response to IKBKE knockdown in both Panc-1 and MiaPaca2 cells (Figure 3.1I, 
and 3.2C), which could also be rescued by expression of the non-targetable 
mIKBKE. We also tested the role of IKBKE in tumorigenicity of the Panc-1 and 
MiaPaca2 cells, as assayed by soft agar colony formation assay. We found that 
IKBKE knockdown led to a significant decrease in soft agar colony formation in 
both the cell lines, and this phenotype could be partially reversed by expression of 
the mIKBKE (Figure 3.1J, and 3.2D). Together our findings suggest that IKBKE is 
regulated by GLI in PDAC, and is essential for the survival, and tumorigenicity of 
human PDAC cells in vitro. 
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Figure 3.1: IKBKE is regulated by GLI and is required for PDAC cell 
transformation 
(A-C) IKBKE mRNA levels in Panc-1 cells in response to repression by Gli3T (A), 
shRNA mediated knockdown of Gli1 (B), and treatment with Gant61 (C). (D) 
Western blot showing IKBKE and β-Actin levels in response to repression by Gli3T 
in Panc-1 cells. Significant decrease in IKBKE mRNA and protein levels is seen in 
response to inhibition of GLI transcriptional activity, suggesting GLI dependent 
expression of IKBKE. (E-F) Immunohistochemistry for IKBKE in 2 month old 
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P48Cre;LSL-KrasG12D (E), and P48Cre;LSL-KrasG12D;R26-Gli1 mouse pancreas 
sections. PanIN lesions from P48Cre;LSL-KrasG12D;R26-Gli1 mice express 
significantly higher levels of IKBKE suggesting possible GLI dependent regulation 
of IKBKE expression in vivo. (G) Quantitative RT-PCR for IKBKE mRNA levels in 
response to knockdown of IKBKE using two different shRNAs in Panc-1 cells. 
Significant IKBKE knockdown is seen. (H-K) Significant decrease in cell 
proliferation (H), increase in apoptosis (I), and decrease in tumorigenicity (K) is 
seen as measured by MTT assay, cleaved-Caspase-3 staining, and soft agar 
assay respectively, in response to knockdown of IKBKE. This phenotype can be 
partially rescued by expression of a non-targetable version of IKBKE (mIKBKE). 
(H) Expression of mIKBKE can be detected by C-terminal myc-tag on the protein. 
 
 
Figure 3.2: IKBKE is required for survival of MiaPaca2 cells in vitro  
(A) Quantitative RT-PCR for IKBKE mRNA levels in MiaPaca2 cells in response to 
shRNA mediated knockdown of IKBKE with two different shRNAs. (B-D) 
 78 
 
Significant decrease in cell proliferation (B), increase in apoptosis (C), and 
decrease in tumorigenicity (D) is seen as measured by MTT assay, cleaved-
Caspase-3 staining, and soft agar assay respectively, in response to knockdown 
of IKBKE. This phenotype can be partially rescued by expression of a non-
targetable version of IKBKE (mIKBKE). (E) Expression of mIKBKE can be detected 
by C-terminal myc-tag on the protein. 
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IKBKE, but not TBK1 acts downstream of KRAS in PDAC 
We have established that GLI regulates an oncogenic program downstream of 
KRAS in PDAC, and IKBKE may act as an oncogenic effector of GLI in PDAC 
cells. IKBKE and the closely related IкB kinase TBK1 share a high degree of 
homology, and are known to have overlapping functions in other contexts163. 
Although TBK1 was not identified in our gene expression analysis, it is known to 
play a role in various malignancies164. In KRAS driven lung adenocarcinoma, dual 
inhibition of IKBKE and TBK1 using a small molecule inhibitor has been shown to 
reduce KRAS downstream signaling activity165. However, the possible role of TBK1 
in pancreatic cancer has not been explored, and a functional connection between 
KRAS and IKBKE/TBK1 in pancreatic cancer has not been established.  
We first examined the expression of both proteins in pancreatic cancer patients. 
We conducted immunohistochemical staining for IKBKE and TBK1 in a Tissue 
Microarray of human pancreatic cancer samples (N=62) and found that while 
IKBKE was highly expressed in a majority of PDAC samples, TBK1 expression 
was minimal (Figure 3.3 A-C). To identify whether IKBKE or TBK1 acts 
downstream of KRAS in PDAC, we conducted shRNA mediated knockdown of 
KRAS in Panc-1 cells. Knockdown of KRAS led to a significant decrease in 
expression of IKBKE, but not TBK1 in Panc-1 cells (Figure 3.3D-E) as measured 
by immunoblotting, and quantitative RT-PCR. To test the requirement of 
IKBKE/TBK1 in PDAC cell transformation, we used two different shRNAs targeting 
either of the proteins and measured the effect of the knockdown on apoptosis, cell 
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viability, and soft agar colony formation. We found that while knockdown of IKBKE 
resulted in a significant increase in apoptosis as measured by relative cleaved-
Caspase-3 staining, TBK1 knockdown did not affect apoptosis (Figure 3.3F). 
IKBKE knockdown also resulted in a significant decrease in cell viability as 
measured by MTT assay in Panc-1 cells, while TBK1 knockdown had little or no 
effect (Figure 3.3G). Similarly, we found that while IKBKE knockdown led to a 
significant decrease in tumorigenicity as measured by soft agar assay in Panc-1 
cells, knockdown of TBK1 did not affect tumorigenicity (Figure 3.3H). Our data 
suggests that in the context of PDAC, IKBKE but not TBK1 is the major oncogenic 
effector of KRAS.   
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Figure 3.3: IKBKE but not TBK1 acts downstream of KRAS in pancreatic 
ductal adenocarcinoma 
(A-C) Immunohistochemistry staining of IKBKE (A), and TBK1 (B) in human PDAC 
samples. (C) Quantification of IKBKE and TBK1 IHC in 62 human PDAC samples 
shows that IKBKE but not TBK1 is highly expressed in a majority of human PDAC 
cases. D) Western blot analysis in Panc-1 cells indicates that IKBKE protein levels 
are downregulated in response to KRAS knockdown. TBK1 protein levels are 
relatively unchanged. E) mRNA analysis using quantitative RT-PCR shows that 
IKBKE mRNA expression is downregulated in response to KRAS knockdown in 
Panc-1 cells. TBK1 mRNA levels remain relatively unchanged. (F-H) shRNA 
mediated knockdown of IKBKE or TBK1 in Panc-1 cells indicates an increase  in 
fold apoptosis measured by cleaved Caspase-3 positive cells (F), decrease in cell 
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viability measured by MTT assay (G), and decrease in tumorigenicity measured by 
soft agar colony formation (H) in response to IKBKE but not TBK1 knockdown. 
Error bars represent Standard Deviation. Statistical significance was determined 
using a Student's two-tailed t-test. * P<0.05; ** P<0.01 
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IKBKE is required for pancreatic neoplasia formation and progression in 
vivo 
In order to test the requirement of IKBKE in pancreatic transformation in vivo, we 
utilized a mouse model carrying whole body knockout of Ikbke166. We first analyzed 
the requirement of IKBKE in pancreatic development, and found that Ikbke-/- mice 
had histologically normal pancreatic architecture at 12 months of age (N=6) as 
compared to wild type mice (Figure 3.4A-B), with normal development of islets, 
acini, and ducts. We conducted immunohistochemical staining to analyze 
expression of the acinar cell marker amylase, and islet cell marker insulin and 
found no significant difference between the expression of these markers in Ikbke-
/- vs wild type mice (Figure 3.4C-F), thus indicating normal pancreatic 
differentiation. These results indicate that IKBKE is not required for development 
of pancreas.  
To test the role played by IKBKE in pancreatic neoplasia, we utilized the mouse 
model described in Chapter II, in which an oncogenic allele of Kras (G12D) is 
targeted to the endogenous locus and expressed specifically in the pancreatic 
epithelium using Cre-recombinase expressed under the P48 (Ptf1a) promoter54. 
As expected, the P48Cre;LSL-KrasG12D mice developed pancreatic intraepithelial 
neoplasia (PanIN) lesions of histological grades ranging from PanIN1-3, 
depending on the age of the mice, with some 12 month old mice displaying full 
blown adenocarcinoma. Using immunohistochemical staining, we found that 
IKBKE expression in the PanIN lesions correlated with the histological grade of the 
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lesions, with increased expression in higher grade lesions, and very high 
expression in the case of adenocarcinoma (Figure 3.5A).  
To achieve simultaneous KRAS activation and IKBKE loss in the pancreas, we 
crossed the P48Cre mice with KrasG12D;Ikbke-/- mice, and analyzed pancreas from 
each of the genotypes at ages 3 months, 6 months, and 12 months. We found that 
the P48Cre;LSL-KrasG12D (N=15) mice developed PanIN grade 1 and instances of 
grade 2 lesions at the age of 3 months, with increased number of PanIN 2 and 3 
grade lesions at 6 months (Figure 3.5C-E). The normal pancreatic architecture was 
lost by 12 month age, with advanced grade lesions covering majority of the 
pancreas, and instances of adenocarcinoma in some mice. In contrast to this, we 
found that pancreas of P48Cre;LSL-KrasG12D;Ikbke-/- mice (N=24) were largely 
normal at all the 3 time points, with some low grade PanIN lesions (Figure 3.5F-
H). Quantification of PanIN lesions from H&E stained sections obtained from all 
the mouse pancreas samples showed significantly delayed onset, and reduced 
intensity of pancreatic neoplasms in P48Cre;LSL-KrasG12D;Ikbke-/- mice (Figure 
3.5I-K).  
We conducted Ki67 staining on stage matched lesions from P48Cre;LSL-KrasG12D 
and P48Cre;LSL-KrasG12D/;Ikbke-/- mice to evaluate differences in proliferation. 
PanIN lesions from P48Cre;LSL-KrasG12D;Ikbke-/- mice had  less Ki67 positive cells 
compared to similar staged lesions from P48Cre;LSL-KrasG12D mice (Figure 3.5L). 
Quantification of Ki67 positive cells from the lesions indicated significantly less 
proliferation in the lesions from P48Cre;LSL-KrasG12D;Ikbke-/- mice (Figure 3.5M). 
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This data indicates that IKBKE loss may impair cell proliferation, and therefore 
delay progression of the PanIN lesions, which is consistent with our finding that 
IKBKE loss leads to loss of cell proliferation in human PDAC cell lines. Our findings 
suggest a critical requirement of IKBKE in the process of KRAS induced pancreatic 
transformation in vivo, and progression of pancreatic neoplasms to 
adenocarcinoma.  
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Figure 3.4: IKBKE is dispensable for pancreatic development 
(A-B) Representative images showing H&E staining of 12 month old wild type (A), 
and Ikbke-/- (B) mouse pancreas. Arrows indicate Acini, Ducts, and Islets. Ikbke-/- 
mice have normal pancreatic architecture and loss of IKBKE does not affect 
development of pancreas.  (C-D) Immunohistochemical staining on 12 month old 
pancreas sections for Insulin in wild type (C), and Ikbke-/- (D) mouse pancreas 
indicates normal islet function. (E-F) IHC for Amylase in 12 month old pancreas 
sections from wild type (E), and Ikbke-/- (F) shows normal acinar function 
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Figure 3.5: IKBKE requirement in KRAS induced Pancreatic Tumorigenesis 
(A) Immunohistochemistry for IKBKE protein levels in wild type mouse pancreas 
(i), and P48Cre;LSL-KrasG12D mouse pancreas in PanIN1 (ii), PanIN2 (iii), PanIN3 
(iv) stage precursor lesions, and full blown Adenocarcinoma (v). IKBKE is not 
expressed in wild type pancreas but is expressed at increasing levels with 
increasing severity of pancreatic neoplasms. (B) Western blot showing IKBKE 
levels in pancreas of 12 month old P48Cre;LSL-KrasG12D and P48Cre;LSL-
KrasG12D;Ikbke-/- mice. IKBKE is not expressed in pancreas from P48Cre;LSL-
KrasG12D;Ikbke-/- mice but is expressed in P48Cre;LSL-KrasG12D mice. (C-E) 
Representative H&E staining images of pancreas of 3 month old (C), 6 month old 
(D), and 12 month old (E) P48Cre;LSL-KrasG12D mice. (F-H) Representative H&E 
staining images of pancreas of 3 month old (C), 6 month old (D), and 12 month old 
(E) P48Cre;LSL-KrasG12D;Ikbke-/- mice. (I-K) Quantification of grade of PanIN 
 88 
 
lesions in age matched P48Cre;LSL-KrasG12D and P48Cre;LSL-KrasG12D;Ikbke-/- 
mouse pancreas at ages 3 months (I), 6 months (J), and 12 months (K). 
Comparison of age matched pancreas indicates significantly delayed initiation and 
progression of pancreatic neoplasms in P48Cre;LSL-KrasG12D;Ikbke-/- mice 
compared to P48Cre;LSL-KrasG12D mice. (L) Immunohistochemistry for Ki67 in 
stage matched pancreas of P48Cre;LSL-KrasG12D (i, iii, v), and P48Cre;LSL-
KrasG12D;Ikbke-/- (ii, iv, vi) mice. (M) Quantification of Ki67 positive cells in PanIN1 
(i), PanIN 2 (ii), and PanIN3 (iii) lesions of P48Cre;LSL-KrasG12D and P48Cre;LSL-
KrasG12D;Ikbke-/- mouse pancreas. Significantly less number of Ki67 positive cells 
in PanIN lesions of P48Cre;LSL-KrasG12D;Ikbke-/- mice compared to P48Cre;LSL-
KrasG12D;Ikbke-/- mice indicates decreased number of proliferative cells. Error bars 
represent Standard Deviation. Statistical significance was determined using a 
Student's two-tailed t-test. * P<0.05; ** P<0.01 
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IKBKE is a direct transcriptional target of GLI, and mediates feedback 
regulation of GLI activity 
As we initially identified IKBKE as a potential GLI target gene in a PDAC cell 
microarray, we decided to further explore the relationship between GLI and IKBKE. 
Consistent with our gene expression data, inhibition of GLI transcriptional activity 
using either the Gli3T repressor, or shRNA mediated knockdown of GLI1 in Panc-
1 cells led to a significant decrease in IKBKE but not TBK1 mRNA levels (Figure 
3.6A), thus implicating IKBKE but not TBK1 as a GLI target gene. Furthermore, 
when we compared mRNA expression levels of IKBKE vs GLI1 in human PDAC 
patient samples, we found a very strong correlation (R = 0.79, P<0.0001) between 
the expression of the two genes (Figure 3.6B).  
In order to test whether IKBKE was a direct transcriptional target of GLI, we 
conducted chromatin immunoprecipitation on Panc-1 cells expressing a Flag-
tagged version of Gli3T. We found significant enrichment of the IKBKE promoter 
region in the ChIPed samples, as well as enrichment of the promoter region of 
PTCH1, which is a known target gene (Figure 3.6C). Sequence analysis of the 
IKBKE promoter region revealed the existence of a candidate GLI binding site 
(GACTTCCCA), which carries a 2 base-pair mismatch to the GLI consensus 
sequence GACCACCCA, 130 bp upstream of the transcriptional start site in the 
IKBKE promoter. In order to test whether GLI regulates transcription of IKBKE by 
binding to its promoter, we cloned the IKBKE promoter region ~300 bp upstream 
of the start site, in a PGL3 luciferase reporter construct. In order to test the 
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specificity of the candidate GLI binding site, we also generated a mutant version 
of the construct in which the candidate GLI binding site was mutated to 
“GGCGCGCC”. We then conducted a luciferase assay in Panc-1 cells with both 
versions of the IKBKE-promoter luciferase, as well as Gli-BS luciferase, which 
carries an 8x GLI binding site upstream of a luciferase reporter. We found that in 
response to the Gli3T repressor, relative expression of the Gli-BS luciferase, and 
luciferase with the IKBKE promoter was significantly downregulated. However, no 
significant difference was seen in expression of the IKBKE promoter luciferase 
carrying the mutant GLI binding site, in response to the Gli3T repressor (Figure 
3.6D). These findings indicate that GLI can regulate transcription of IKBKE by 
binding to its promoter region, and that mutation of the GLI binding site ablates GLI 
regulation of IKBKE transcription.  
Although GLI transcriptional activity has been shown to be important in pancreatic 
cancer, the upstream regulation of GLI activity in PDAC has not been well 
characterized. In the context of PDAC, it is known that GLI acts independently of 
its canonical upstream regulators Hedgehog, PTCH1, and SMO143, however, 
regulation of GLI at the post-translational level is not well studied, although both 
GLI1 activity and localization has been shown to be regulated in other cellular 
contexts167,168,169. Here, we further explored the potential role of IKBKE in the 
regulation of GLI. We found that in Panc-1 cells, shRNA mediated knockdown of 
IKBKE led to a significant decrease in mRNA levels of the GLI target genes GLI1, 
FOXA2, and PTCH1 (Figure 3.6E). Pancreas of P48Cre;LSL-KrasG12D;Ikbke-/- mice 
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showed considerably lower levels of mRNA of the GLI target genes compared to 
P48Cre;LSL-KrasG12D mice (Figure 3.6F). These findings suggest that IKBKE 
plays a role in regulation of GLI transcriptional activity. As GLI1 is a shuttling 
protein, and the activity of GLI1 is regulated by the subcellular localization of the 
protein167, we tested the role played by IKBKE in regulation of subcellular 
localization. We ectopically expressed a GFP-fusion version of GLI1 in 293T cells 
to visualize the localization of the protein. We found that when expressed 
ectopically, the Gli1-GFP was localized mostly to the cytoplasm in punctate 
structures (Figure 3.6G-i,iv). However, when we ectopically expressed wild type 
IKBKE, but not a kinase-dead version of IKBKE (K38A), the Gli1-GFP proteins 
were translocated to the nucleus (Figure 3G-ii, iii, v, vi). This data shows that 
IKBKE kinase activity promotes nuclear translocation of GLI1. To further test the 
role played by IKBKE in regulating GLI activity and localization, we utilized a 
mutant version of GLI1 (Gli1-AHA) that is constitutively localized to the nucleus167. 
In 293T cells, we found that co-expression of IKBKE, but not IKBKE-K38A led to a 
synergistic increase in the transcriptional activity of GLI1, as measured by Gli-BS 
luciferase expression (Figure 3.6H). However, co-expression of IKBKE or IKBEK-
K38A did not significantly affect the activity of Gli1-AHA. As Gli1-AHA is 
constitutively localized to the nucleus, unlike wild type GLI1 which shuttles 
between the nucleus and cytoplasm, our results indicate that IKBKE regulates GLI 
activity primarily by regulating nuclear localization of the protein. Taken together, 
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our findings point to a potential reciprocal interaction between IKBKE and GLI 
downstream of KRAS in PDAC cells.   
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Figure 3.6: Reciprocal GLI-IKBKE Signaling in Pancreatic Ductal 
Adenocarcinoma 
(A) Quantitative RT-PCR in Panc-1 cells showing GLI1, IKBKE, and TBK1 mRNA 
expression after inhibition of GLI activity using a dominant negative GLI (Gli3T), or 
an shRNA targeting GLI1. While GLI1 and IKBKE expression is decreased upon 
inhibition of Gli activity, TBK1 expression is unchanged. (B) Correlation of GLI1 
and IKBKE mRNA expression in 229 human PDAC tissue samples. Pearson 
coefficient R value of 0.79 indicates high degree of correlation between GLI1, and 
IKBKE expression in the tumors.(C) Quantitative PCR of DNA enriched using ChIP 
against Flag-tag in Panc-1 cells infected with Gli3T-Flag indicates significant 
enrichment of IKBKE promoter region as well as the promoter of a known GLI 
target gene (PTCH1). (D) Relative luciferase activity in Panc-1 cells of Gli-BS 
Luciferase, IKBKE promoter luciferase containing the GLI binding site in IKBKE 
promoter cloned in a luciferase reporter, and IKBKE promoter carrying a mutated 
GLI binding site cloned in a luciferase reporter. While activity of Gli-BS luciferase, 
and IKBKE promoter luciferase is significantly decreased in response to inhibition 
using dominant-negative Gli3T, the activity of IKBKE promoter mutant luciferase is 
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relatively unchanged. (E) Quantitative RT-PCR indicates that GLI target gene 
expression in Panc-1 cells is significantly decreased in response to shRNA 
mediated knockdown of IKBKE. (F) Quantitative RT-PCR in tissue samples 
indicates significantly reduced GLI target gene expression in 6 month old 
P48Cre;LSL-KrasG12D;Ikbke-/- mouse pancreas compared to age-matched 
P48Cre;LSL-Kras;G12D pancreas. (G) Subcellular localization of a Gli1-GFP fusion 
gene transfected in 293T cells with (i-iii) and without (iv-vi) over lay with DAPI. 
While Gli1 is localized mainly in the cytoplasm without IKBKE expression (i, iv), 
IKBKE expression drives nuclear localization of GLI1 (ii, v). Expression of a kinase-
dead version of IKBKE (K38A) causes cytoplasmic retention of GLI1 (iii, vi). (H) 
Co-expression of IKBKE with GLI1 synergistically increases GLI transcriptional 
activity as measured by Gli-BS Luciferase expression in 293 cells. IKBKE 
expression has no effect on the activity of Gli1-AHA, a mutant form of Gli1 that is 
constitutively localized to the nucleus. Kinase-dead version of IKBKE can inhibit 
transcriptional activity of GLI1 but not Gli1-AHA. Error bars represent Standard 
Deviation. Statistical significance was determined using a Student's two-tailed t-
test. * P<0.05; ** P<0.01 
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Regulation of NF-кB signaling by IKBKE 
IKBKE was initially identified as an IкB kinase involved in regulation of NF-кB 
signaling170. As NF-кB signaling has been implicated in pancreatic cancer44,73, and 
as the oncogenic activity of IKBKE has been linked to its ability to activate NF-кB 
in other cancers162,165, we tested the role played by IKBKE in NF-кB activation in 
the context of PDAC. We found that while in a p65 luciferase assay in 293T cells 
IKBKE can strongly activate NF-кB signaling in an IкB dependent manner (Figure 
3.7A), shRNA mediated knockdown of IKBKE in Panc-1 PDAC cells leads to only 
a modest downregulation of known NF-кB target genes (Figure 3.7B). Also, we do 
not see a significant downregulation of NF-кB target gene mRNA levels in 
pancreas of P48Cre;LSL-KrasG12D;Ikbke-/- mice compared to P48Cre;LSL-KrasG12D 
mice (Figure 3.7C).  
Nuclear localization of the NF-кB subunit p65 is a marker for NF-кB pathway 
activation, and IKBKE is known to drive p65 nuclear translocation through 
inactivation of IкB. To test NF-кB pathway activation, we used immunoblotting to 
compare the levels of p65 in nuclear and cytoplasmic fractions of Panc-1 cells after 
shRNA mediated knockdown of IKBKE. We found that while IKBKE knockdown 
led to a modest decrease in levels of p65 in the nuclear fraction (Figure 3.7D), 
significant amounts of p65 was still present in the nucleus, which may account for 
the sustained NF-кB target gene expression after IKBKE knockdown. In order to 
study the relationship between NF-кB pathway activation and IKBKE protein levels 
in patients, we conducted immunohistochemistry for p65, and IKBKE on a tissue 
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microarray of human PDAC samples. p65 localization in the tumor samples was 
classified either as predominantly nuclear, or predominantly cytoplasmic. Staining 
intensity for IKBKE protein in tumors was graded as either low, medium, or high. 
Analysis of p65 localization vs IKBKE protein levels was conducted for each 
sample and a Pearson correlation was obtained between the two. Analysis 
revealed a lack of significant correlation between p65 localization and IKBKE 
protein levels (R=0.16, P>0.05, N=62) in the tumor samples (Figure 3.7E-F).  
Furthermore, we compared subcellular localization of p65 in stage-matched PanIN 
lesions of P48Cre;LSL-KrasG12D;Ikbke-/- and P48Cre;LSL-KrasG12D mice using 
immunohistochemistry. We found that even with Ikbke knockout, nuclear p65 was 
present in the PanIN lesions and there was no significant difference in nuclear 
localization of p65 between lesions of P48Cre;LSL-KrasG12D;Ikbke-/- and 
P48Cre;LSL-KrasG12D mice (Figure 3.7G-I). Our findings indicate that while IKBKE 
is capable of regulating the NF-кB pathway, in the context of PDAC it contributes 
only modestly to NF-кB regulation, since significant amount of NF-кB pathway 
activity is still maintained upon IKBKE loss. This also indicates that IKBKE 
oncogenic activity in the context of pancreatic cancer may be mediated by NF-кB 
independent mechanisms.     
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Figure 3.7: Regulation of NF-кB activity by IKBKE 
(A) NF-кB luciferase activity in 293T cells is significantly increased in response to 
IKBKE ectopic expression. IKBKE activation of NF-кB activity can be inhibited by 
a dominant negative version of IкB suppressor. (B) Quantitative RT-PCR shows 
that NF-кB target gene mRNA expression in Panc-1 cells is modestly 
downregulated in response to shRNA mediated knockdown of IKBKE. (C) 
Quantitative RT-PCR of NF-кB target gene mRNA expression in pancreas of 6 
month old P48Cre;LSL-KrasG12D, and P48Cre;LSL-KrasG12D;Ikbke-/- mice. No 
significant decrease in NF-кB target gene expression is seen in response to 
knockout of Ikbke in mice. (D) Western blot showing RelA (p65) in nuclear and 
cytoplasmic fractions of Panc-1 cells with and without shRNA knockdown of 
IKBKE.  PCNA and Tubulin are used as controls for nuclear and cytoplasmic 
fractions respectively. No significant difference is seen in p65 subcellular 
localization in response to IKBKE knockdown. (E) Representative images 
comparing immunohistochemistry of IKBKE (i,ii) and p65 (iii, iv) in matched human 
PDAC tissue samples. (F) Correlation between subcellular localization of p65 and 
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IKBKE protein levels in 62 human PDAC samples. Pearson coefficient R = 0.15 
does not indicate a significant correlation (P>0.05) between IKBKE protein levels 
and subcellular localization of p65. (G-I) Immunohistochemistry for p65 in stage 
matched PanIN lesions in P48Cre;LSL-KrasG12D (G), and P48Cre;LSL-
KrasG12D;Ikbke-/- (J) mouse pancreas. Quantification of p65 subcellular localization 
(I) indicates no significant differences in nuclear vs cytoplasmic p65 in 
P48Cre;LSL-KrasG12D and P48Cre;LSL-KrasG12D;Ikbke-/- mouse PanIN lesions. 
Error bars represent Standard Deviation. Statistical significance was determined 
using a Student's two-tailed t-test. * P<0.05; ** P<0.01 
 
 
  
 99 
 
IKBKE regulates AKT activation in PDAC 
As we found that NF-кB regulation may not account for IKBKE tumorigenicity in 
the context of PDAC, we decided to evaluate alternative mechanisms through 
which IKBKE may promote tumorigenesis. The PI3K/AKT signaling pathway is 
known to act downstream of KRAS in PDAC, and play a critical role in 
transformation, apoptosis evasion, and chemoresistance146,171. We have also 
found that GLI can regulate phosphorylation of AKT in pancreatic cancer cells148. 
Also, IKBKE is known to phosphorylate AKT in vitro and in cancer cells172. Here, 
we decided to test whether IKBKE plays a role in regulation of AKT 
phosphorylation in PDAC. We found that IKBKE knockdown in Panc-1 cells led to 
a significant decrease in the phosphorylation of AKT but not ERK (Figure 3.8A), 
and phospho-AKT levels were significantly decreased in the stage-matched PanIN 
lesions of P48Cre;LSL-KrasG12D;Ikbke-/- mouse pancreas compared to 
P48Cre;LSL-KrasG12D mice (Figure 3.8C-F).  
Normally, the mTORC2 complex is known to phosphorylate AKT at Serine-473 and 
mediate AKT activation108. However, we found that in Panc-1 cells, basal level of 
AKT phosphorylation at both Serine-473, and Threonine-308 was maintained even 
after mTOR inhibition using the small molecule inhibitor Torin1 (Figure 3.8B). 
Furthermore, this basal phosphorylation of AKT was significantly reduced following 
knockdown of IKBKE in combination with mTOR inhibition. In order to test whether 
the relationship between IKBKE expression and AKT phosphorylation in patients, 
we conducted immunohistochemistry for IKBKE and phospho-AKT Serine-473 on 
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a tissue microarray of human PDAC samples. We found a significant correlation 
between IKBKE protein levels and AKT phosphorylation at Serine-473 in the tumor 
samples (R=0.606, P<0.0001, N=62) (Figure 3.8G-H).  Our findings suggest that 
IKBKE may regulate AKT phosphorylation in PDAC both in vitro and in vivo. 
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Figure 3.8: IKBKE activates AKT in Pancreatic Ductal Adenocarcinoma 
(A) Western blot showing phosphorylation of AKT and ERK in serum starved Panc-
1 cells in response to shRNA mediated IKBKE knockdown. IKBKE knockdown 
leads to decrease in phosphorylation of AKT at Serine-473, but not ERK 
phosphorylation. (B) Western blot of Panc-1 cells with or without inhibition of 
mTOR using Torin1, and shRNA mediated knockdown of IKBKE. Inhibition of 
mTOR or IKBKE individually leads to decrease in phosphorylation of AKT at 
Serine-473 and Threonine-308. Combined inhibition of mTOR and IKBKE leads to 
synergistic inhibition of AKT phosphorylation at Serine-473 and Threonine-308. (C-
F) Immunohistochemistry for AKT phosphorylation at Serine-473 (C, D), and 
Threonine-308 (E, F) in stage matched PanIN lesions of P48Cre;LSL-KrasG12D  (C, 
E), and P48Cre;LSL-KrasG12D;Ikbke-/- (D,F) mouse pancreas. P48Cre;LSL-
KrasG12D;Ikbke-/- PanIN lesions have significantly reduced Akt phosphorylation 
compared to P48Cre;LSL-KrasG12D lesions. (G) Correlation of IKBKE protein levels 
and AKT Serine-473 phosphorylation levels in human PDAC tissue microarray. 
Pearson coefficient of R=0.606 shows significant correlation (P<0.0001) between 
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IKBKE protein levels and AKT phosphorylation. (H) Representative images of 
immunohistochemistry for IKBKE (i-iii) and phospho-AKT Serine-473 in matched 
human PDAC tissue samples. Significant correlation is seen between relative 
IKBKE expression and AKT phosphorylation. 
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IKBKE regulates AKT reactivation post-mTOR inhibition 
While mTOR inhibitors have been approved for treatment of certain 
malignancies173,114,174, they have not been effective in the treatment of pancreatic 
adenocarcinoma22. One of the problems concerning the use of mTOR inhibitors in 
the clinic is the reactivation of AKT post-inhibition of mTOR175,176. While 
compensatory activation of upstream RTK signaling, and subsequent 
phosphorylation of AKT at Threonine-308 has been shown to be a mechanism of 
resistance to mTOR inhibition in breast cancer177 the underlying mechanism of 
resistance to mTOR inhibition in PDAC is not known.  
When we treated Panc-1 cells with the mTOR inhibitor Torin1, we found that while 
AKT phosphorylation at Serine-473 and Threonine-308 was inhibited 6 hours post-
treatment, phosphorylation at both the sites was subsequently restored in the 
presence of serum 12 hours after treatment with the inhibitor (Figure 3.9A). 
Phosphorylation of other mTOR targets S6K and 4EBP1 continued to be inhibited 
even 24 hours after treatment, thus indicating that the reactivation of AKT 
phosphorylation was mTOR-independent. These findings were in contrast to the 
earlier findings in breast cancer cells177  which showed reactivation of AKT 
phosphorylation only at Threonine-308 but not Serine-473, thus suggesting that 
the AKT reactivation in pancreatic cancer cells is mediated by a different 
underlying mechanism. As we have found that IKBKE can phosphorylate at both 
Serine-473, and Threonine-308, and maintain basal level of AKT phosphorylation 
in the absence of mTOR, we decided to test the role of IKBKE in AKT reactivation. 
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We found that shRNA mediated knockdown of IKBKE ablated the reactivation of 
AKT post-inhibition of mTOR in Panc-1 cells (Figure 3.9B). Furthermore, we found 
that while treatment with the mTOR inhibitor alone did not affect survival of PDAC 
cells, knockdown of IKBKE sensitized Panc-1 cells to the mTOR inhibitor, and 
IKBKE knockdown combined with mTOR inhibition led to a synergistic decrease in 
cell viability (Figure 3.9C). Combined mTOR inhibition with IKBKE knockdown also 
led to a significant increase in apoptosis as measured by cleaved-Caspase-3 
staining (Figure 3.9D), and a decrease in tumorigenicity in Panc-1 cells as 
measured by soft agar assay (Figure 6E). 
As we have previously seen that GLI can regulate AKT phosphorylation in PDAC, 
and we have found IKBKE to be a downstream mediator of GLI activity, we decided 
to test the role played by GLI in AKT reactivation. We found that similar to the effect 
of IKBKE knockdown, inhibition of GLI using a small molecule inhibitor Gant61 in 
Panc-1 cells prevented reactivation of AKT post-inhibition of mTOR (Figure 3.10A). 
As Gant61 treatment leads to decrease in IKBKE mRNA levels along with those of 
other Gli target genes (Figure 3.10B), the effect of Gant61 on AKT reactivation can 
be attributed to its inhibition of GLI, and the subsequent transcriptional inhibition of 
IKBKE. We also found that Gant61 treatment phenocopies the effect of combined 
IKBKE and mTOR inhibition by sensitizing Panc-1 cells to Torin1, and combined 
Gant61 and Torin1 treatment synergistically increases apoptosis, and decreases 
tumorigenicity of the cells (Figure 3.10C-E). Our findings implicate combined 
GLI/IKBKE signaling as playing a crucial role in reactivation of AKT post-mTOR 
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inhibition. This AKT reactivation IKBKE may be responsible for resistance towards 
mTOR small molecule inhibitors in PDAC. 
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Figure 3.9: IKBKE mediates AKT reactivation post-mTOR inhibition 
(A) Western blot showing phosphorylation of AKT and other mTOR substrates in 
response to treatment with Torin1 in Panc-1 cells. AKT phosphorylation at Serine-
473 and Threonine-308, which is inhibited immediately after mTOR inhibition by 
Torin1, is subsequently recovered. Sustained inhibition phosphorylation of mTOR 
substrates S6K and 4EBP1 suggests that mTOR activity is inhibited and AKT re-
phosphorylation is independent of mTOR activity. (B) Western blot of AKT and 
other mTOR substrates in response to treatment of Torin1 in Panc-1 cells with 
shRNA mediated knockdown of IKBKE. AKT phosphorylation is not recovered after 
inhibition of mTOR suggesting IKBKE plays a role in in AKT re-phosphorylation 
post-mTOR inhibition. (C) Relatve cell viability of Panc-1 cells measured by MTT 
assay 5 days after treatment with increasing dosage of the mTOR inhibitor Torin1 
in the presence and absence of IKBKE knockdown. While mTOR inhibition alone 
is not sufficient to significantly affect cell viability, IKBKE knockdown sensitizes 
cells to mTOR inhibition and leads to dosage dependent decrease in cell viability. 
(D) Cleaved-Caspase-3 staining in Panc-1 cells indicates that while mTOR 
inhibition alone using Torin1 does not lead to a significant increase in apoptosis, 
combined inhibition of IKBKE and mTOR leads to a significant increase in 
apoptosis. (E) Soft agar colony formation assay in Panc-1 cells indicates that while 
mTOR inhibition alone does not affect tumorigenicity of the cells, combined 
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inhibition of mTOR and IKBKE leads to significant decrease in tumorigenicity. Error 
bars represent Standard Deviation. Statistical significance was determined using 
a Student's two-tailed t-test. * P<0.05; ** P<0.01 
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Figure 3.10: GLI regulation of AKT reactivation post-mTOR inhibition 
(A) AKT phosphorylation at Serine-473 is inhibited in Panc-1 cells 6 hours after 
treatment with mTOR inhibitor Torin1. AKT phosphorylation is restored after 12 
hours of treatment with Torin1. In the presence of GLI inhibitor Gant61, restoration 
of AKT phosphorylation is inhibited. (B) Quantitative RT-PCR shows that treatment 
of Panc-1 cells with Gant61 inhibits mRNA expression of GLI target genes 
including IKBKE. (C) Apoptosis in Panc-1 cells measured by cleaved Caspase-3 
staining. Torin1 treatment alone does not significantly affect apoptosis. Treatment 
with Gant61 causes an increase in apoptosis in Panc-1 cells. Combined treatment 
with Torin1 and Gant61 synergistically increases apoptosis in Panc-1 cells. (D) 
Viability of Panc-1 cells as measured by MTT assay after 5 days of treatment. 
Treatment with Torin1 does not affect cell viability. Treatment with Gant61 
significantly decreases cell viability. Combined treatment with Torin1 and Gant61 
synergistically decreases viability of Panc-1 cells. (E) Tumorigenicity of Panc-1 
cells measured by soft agar colony formation. Treatment with Torin1 does not 
affect soft agar colony formation by Panc-1 cells. Treatment with Gant61 leads to 
a significant decrease in soft agar colony formation by Panc-1 cells. Combined 
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treatment with Torin1 and Gant61 leads to a synergistic decrease in soft agar 
colony formation by Panc-1 cells. Error bars represent Standard Deviation. 
Statistical significance was determined using a Student's two-tailed t-test. * 
P<0.05; ** P<0.01  
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Materials and Methods 
Mouse strains 
P48Cre, and LSL-KrasG12D mouse strains have been described in Chapter II. Ikbke-
/- mice166 were obtained from Jackson Laboratories. P48Cre;LSL-KrasG12D;Ikbke-/- 
mice were obtained via interbreeding P48Cre mice with LSL-KrasG12D;Ikbke-/- mice. 
All mouse experiments were performed according to the guidelines of IACUC at 
University of Massachusetts Medical School.  
Tissue collection and histology:  
Upon euthanasia, pancreatic tissue was fixed in 4% (wt/vol) paraformaldehyde for 
24 hours. For paraffin sections, tissue was dehydrated and embedded in paraffin 
blocks and cut at a thickness of 6 µm. Paraffin sections were stained with 
hematoxylin and eosin (H&E) using standard reagents and protocols. Human 
PDAC tissue microarray was obtained from Shanghai Outdo Biotech. 
Immunohistochemistry, immunofluorescence, and immunoblotting:  
For immunohistochemistry, high-temperature antigen retrieval was conducted in 
Sodium Citrate solution (pH 6.0) on paraffin sections for 30 minutes. Sections were 
blocked in a buffer containing 5% (wt/vol) BSA and 0.1% (vol/vol) Triton X-100 in 
PBS and then were incubated overnight at 4 °C in primary antibodies diluted in 
blocking buffer. Primary antibodies used were: Ki67 (1:500, Abcam), phospho- 
AKT (1:50, Cell Signaling), IKBKE (1:50, Santa Cruz) for mouse sections, IKBKE 
(1:100, Sigma) for human sections, TBK1 (1:100, Cell Signaling), p65 (1:50, Cell 
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Signaling), Amylase (1:800, Sigma), and Insulin (1:100, Abcam). Signal detection 
was accomplished with biotinylated secondary antibodies in the Vectastain ABC 
kit (Vector Labs). For immunofluorescence, primary antibodies used were: 
Glucagon (1:3000, gift of Dr. Andrew Leiter, UMMS), Amylase (1:800, Sigma), 
Insulin (1:100, Abcam). 
For immunofluorescence, cells grown in 8 well chamber slides were fixed for 5 
minutes in 4% paraformaldehyde, blocked in a buffer containing 5% (vol/vol) sheep 
serum, 1% (vol/vol) FBS, and 0.1% (vol/vol) Triton X-100 in PBS for 1 hour, and 
then incubated with primary antibody overnight. Cleaved-Capase-3 antibody 
(1:400, Cell signaling) was used for apoptosis assay. Alexa Fluor fluorescent 
conjugated secondary antibody (Invitrogen) was used for detection at a 
concentration of 1:500 diluted in blocking buffer. Slides then were mounted in 
mounting medium containing DAPI. 
For immunoblotting, the primary antibodies used were FlagM2-HRP (1:1,000’ 
Sigma); β-Actin (1:1,000, Sigma); phospho-AKT S473 (1:1,000, Cell Signaling), 
phospho-Akt T308 (1:1000, Cell Signaling), phospho-ERK (1:1,000, Cell 
Signaling); total AKT (1:1,000, Cell Signaling); Total ERK (1:1,000, Cell Signaling); 
IKBKE (1:1,000; Sigma), TBK1 (1:1000, Cell Signaling), phospho-S6K (1:1000, 
Cell Signaling), phospho-4EBP1 (1:1000 Cell Signaling), p65 (1:1000 Cell 
Signaling), PCNA (1:1000 Abcam), β-Tubulin (1:1000 Cell Signaling),  and Myc 
(1:1,000; Developmental Studies Hybridoma Bank). HRP-conjugated secondary 
antibodies used for detection were obtained from Jackson Laboratories. 
 112 
 
 
Cell proliferation, apoptosis and soft-agar assays:  
Cell proliferation, apoptosis, and soft-gar assays were conducted as described in 
Chapter II. 
Lentiviral shRNA knockdown and rescue experiments: 
Cells were infected with pLKO-based lentiviruses encoding shRNAs targeting 
human Gli1 (shGLI1#1: CATCCATCACAGATCGCATTT; shGLI1#2: 
GCTCAGCTTGTGTGTAATTAT), human KRAS (shKRAS: 
GAGGGCTTTCTTTGTGTATTT) human TBK1 (shTBK1#1: 
GCAGAACGTAGATTAGCTTAT; shTBK1#2:  
GCGGCAGAGTTAGGTGAAATT) and human IKBKE (shIKBKE#1: 
TGGGCAGGAGCTAATGTTTCG; shIKBKE#2: 
GAGCATTGGAGTGACCTTGTA). Infected cells were selected in 5 μg/mL 
puromycin for 4 days prior to conducting assays. 
Luciferase reporter analysis:  
GliBS-Luc was described in Chapter II. NF-κB luciferase (p65-Luc) was a gift from 
Dr. Francis Chan (University of Massachusetts Medical School, Worcester, MA). 
Reporters were co-transfected with Renilla expression plasmids, and expression 
vectors for Gli3T, IKBKE, IKBKE K38A, IкB or Gli1-AHA using lipofectamine. For 
Gli1 knockdown, the cells were cotransfected with shRNAs targeting GLI1 along 
with NF-κB luciferase and Renilla expression plasmids. For Gant61 treatment, the 
Panc1 cells were co-transfected with NF-κB reporter and Renilla Luciferase and 
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then were treated with 5 μM or 10 μM Gant61 6 hours after transfection. IKBKE 
promoter luciferase was generated by cloning a 300 bp region upstream of the 
human IKBKE transcription start site into a PGL3 luciferase vector. Luciferase 
assays were conducted 48 hours after transfection using the dual-luciferase 
reporter kit (Promega). Assays were conducted in triplicate. 
Quantitative RT-PCR:  
cDNA synthesis was conducted using Invitrogen SuperScript II kit. Primers used 
for qRT-PCR were human IKBKE (forward: 5′-TGCGTGCAGAAGTATCAAGC-3′; 
reverse: 5′-TACAGGCAGCCACAGAACAG-3′); mouse Ikbke (forward: 5′-
GCGGAGGCTGAATCACCAG-3′; human GAPDH (forward: 5′-
ATGGGGAAGGTGAAGGTCG-3′; reverse: 5′-GGGGTCATTGATGGCAACAATA-
3′); mouse Gapdh (forward: 5′-AGGCCGGTGCTGAGTATGTC-3′; reverse: 5′-
TGCCTGCTTCACCACCTTCT-3′); human GLI1 (forward: 5′-
CCAGCGCCCAGACAGAG-3′; reverse:5′-GGCTCGCCATAGCTACTGAT-3′); 
mouse Gli1 (forward: 5′-GTCGGAAGTCCTATTCACGC-3′; reverse: 5′-
CAGTCTGCTCTCTTCCCTGC-3′); human PTCH1 (forward: 5′-
CCACAGAAGCGCTCCTACA-3′; reverse 5′-CTGTAATTTCGCCCCTTCC-3′); 
mouse Ptc1 (forward: 5′-AACAAAAATTCAACCAAACCTC-3 ′reverse: 5′-
TGTCTTCATTCCAGTTGATGTG-3′); human IL1A (forward: 
ATCATGTAAGCTATGGCCCACT; reverse: CCTTCCCGTTGGTTGCTACTA), 
mouse Il1a (forward: 5’- TCTATGATGCAAGCTATGGCTCA-3’; reverse: 5’- 
CGGCTCTCCTTGAAGGTGA-3’); human TNFA (forward: 
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CCTCTCTCTAATCAGCCCTCTG; reverse: GAGGACCTGGGAGTAGATGAG), 
mouse Tnf (forward: 5’- CAGGCGGTGCCTATGTCTC-3’; reverse: 5’- 
CGATCACCCCGAAGTTCAGTAG-3’); human BCL2L1 (forward: 
CTGCTGCATTGTTCCCATAG-3’; reverse: 5’-TTCAGTGACCTGACATCCCA-3’), 
mouse Bcl2l1 (forward: 5’- ACATCCCAGCTTCACATAACCC-3’; reverse: 5’- 
CCATCCCGAAAGAGTTCATTCAC-3’); human BCL2 (forward: 5’-
ATGTGTGTGGAGAGCGTCAA-3’; reverse: 5’-CGTACAGTTCCACAAAGGCA-
3’); and mouse Bcl2 (forward: 5’-GCTACCGTCGTGACTTCGC-3’; reverse: 5’- 
CCCCACCGAACTCAAAGAAGG-3’). All qPCR assays were conducted in 
triplicate. 
Nuclear and cytoplasmic fractionation 
For nuclear and cytoplasmic fractionation, Panc-1 cells were infected either with 
shIKBKE#1, or with an shRNA targeting GFP, and selected with puromycin for 4 
days. Nuclear and cytoplasmic fractions were separated using a kit from G 
Biosciences according to manufacturer’s protocol. 
Gli1 subcellular localization 
293T cells seeded in an 8 well chamber slide were co-transfected with a human 
GLI1 expression vector fused to a C-terminal GFP-tag, along with either an IKBKE 
expression vector, IKBKE-K38A expression vector, or a control vector. The cells 
were fixed in 4% paraformaldehyde and mounted with a mounting medium 
containing DAPI 48 hours after transfection. 
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Chapter IV: DISCUSSION 
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GLI requirement in KRAS induced pancreatic tumorigenesis 
Although significance of known effectors of KRAS such as PI3K/AKT, and 
RAF/MEK/ERK has been well characterized in PDAC50, effectors of KRAS 
downstream signaling at the transcriptional level remain elusive. Crosstalk 
between the Sonic Hedgehog pathway, and KRAS signaling has been 
reported142,139. While previous reports had implicated the transcription factor GLI1 
as a potential effector of KRAS in human cell lines, an in vivo requirement for GLI 
transcriptional activity in PDAC had not been established143. 
Here, using a dominant repressor allele of GLI3 (Gli3T), that inhibits all GLI 
mediated transcriptional activation, we demonstrate for the first time that GLI 
transcriptional activity in the epithelium is specifically required for pancreatic tumor 
formation in vivo, although it is dispensable for normal pancreatic development. To 
achieve this, we used a mouse model of pancreatic transformation with oncogenic 
KRAS activation in the pancreas, that models pancreatic neoplasia initiation and 
progression, as well as a model of pancreatic adenocarcinoma with p53 
inactivation in combination with oncogenic KRAS (KPC model). We find that GLI 
inhibition prevents formation of early PanIN lesions even in the presence of 
oncogenic KRAS, thus indicating that GLI transcriptional activity is required for 
pancreatic tumor initiation. Our in vivo findings are further supported by in vitro 
experiments which show that Gli3T expression can prevent oncogenic KRAS 
induced proliferation in pancreatic ductal epihelial cells (PDECs), and also 
abrogate KRAS mediated survival of these cells in response to Cyclohexamide 
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treatment148.  Together, these data suggest that GLI transcriptional activity plays 
an essential role in mediating transformation of the pancreatic epithelium. 
Furthermore, we find that GLI inhibition significantly extends survival in a mouse 
model of pancreatic adenocarcinoma (KPC model). Although mice carrying the 
Gli3T transgene still developed tumors, isolation of cells from tumors that arise 
from the mice carrying the Gli3T allele showed that the cells failed to undergo 
recombination and do not express Gli3T. This indicates that the tumors that were 
developed with delayed latency in these mice arose from a population of cells that 
was deficient in Gli3T, thus highlighting the importance of GLI transcriptional 
activity in pancreatic tumorigenesis. 
Our findings implicate GLI as essential not only for the initiation of pancreatic 
transformation, but also for progression to full blown Adenocarcinoma. In addition 
to the in vivo mouse models, we also show that GLI transcriptional activity is 
required for tumorigenicity of human PDAC cell lines in vitro. Together, our data 
implicates GLI as an oncogenic effector of KRAS required for pancreatic 
tumorigenesis, and provides proof of concept for therapeutic targeting of GLI in 
PDAC.  
A caveat of our loss of function model was the use of a dominant-negative 
repressor allele of GLI to inhibit transcriptional activity, instead of genetic ablation 
of the GLI proteins. GLI1 and GLI2 are known to have overlapping functions in 
various contexts130, and Gli1-/-;Gli2-/- mice have severe developmental defects178, 
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which necessitated the use of a conditional dominant-negative repressor in our 
model. While the possibility of the Gli3T repressor having some off-target effects 
cannot be excluded, our in vitro studies indicate that repression of GLI activity by 
Gli3T is specific (Fig. 2.1), and we find that the in vitro effect of Gli3T induced 
repression can be replicated by shRNA mediated knockdown of GLI1 and also 
treatment with the GLI small molecule inhibitor Gant61, which supports our 
conclusions. However, another more robust approach to test our findings further 
would be to develop a conditional knockout allele of Gli1, and combine it with Gli2 
conditional knockout to specifically delete both Gli1 and Gli2 in the pancreatic 
epithelium in the background of oncogenic Kras.  
GLI1/2/3 in pancreatic transformation: 
While our loss of function model establishes the requirement for GLI transcriptional 
activity in pancreatic tumorigenesis, the Gli3T allele acts as a dominant negative 
repressor for all the GLI transcription factors, and hence does not distinguish 
between the role played by individual GLI proteins. In order to study the role of 
individual GLI transcription factors in PDAC, we utilized an allele of wild type Gli1, 
and an N-terminal truncated allele of Gli2 (Gli2ΔN) knocked into the Rosa26 locus. 
The N-terminal truncated version of GLI2 was used because unlike GLI1, GLI2 
carries a repressor domain at the N-terminal which suppresses GLI2 activator 
function. We also utilized a conditional knockout allele of Gli3 (Gli3fl/fl) to test the 
role played by the Gli3 repressor in pancreatic transformation, which has 
previously not been studied. 
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Our findings suggest that the activation of GLI1 or GLI2 alone, in the absence of 
oncogenic KRAS is not sufficient to initiate pancreatic transformation, and mice 
with GLI1/2 activation in the pancreatic epithelium have largely normal pancreatic 
architecture and differentiation. These findings are in contrast to an earlier report 
that showed that GLI2 activation alone was sufficient to drive formation of 
undifferentiated tumors in the pancreas139. However, this difference in phenotype 
may be explained by a difference in the design of the two studies. In our 
experiment, the Ptf1a (P48) promoter was used to drive expression of Cre, which 
is expressed later on in the pancreatic progenitor cells compared to the Pdx1 
promoter used in the other study179,180. Also, the Gli2 transgene used in our study 
was expressed from the Rosa26 locus, whereas the Gli2 allele used in the other 
study (Cleg2) was expressed under the control of the CAGGS promoter, a highly 
active hybrid CMV/β-Actin promoter. Differences in expression levels of GLI2 may 
account for the difference in phenotype seen in our studies. This possibility can be 
tested by comparing expression levels of GLI2 in the two different models.  
While GLI1/2 activation alone is not sufficient to drive pancreatic tumorigenesis, 
we find that both GLI1 and GLI2 can cooperate with oncogenic KRAS in pancreatic 
transformation. Ectopic expression of either GLI1 or GLI2ΔN in the pancreatic 
epithelium led to the accelerated formation of advanced PanIN lesions in mice. 
While mice with oncogenic KRAS expression in pancreas develop PanIN lesions, 
at the age of 2 months most of the pancreas display normal architecture with only 
a few low grade PanIN lesions. In contrast, we found that GLI1 or GLI2ΔN ectopic 
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expression in combination with oncogenic KRAS led to the formation of advanced 
PanIN3 grade lesions at the age of 2 months. Most of these mice did not survive 
past 2 months of age, in contrast to mice with oncogenic KRAS activation alone, 
which lived past 12 months, thus indicating a dramatically reduced survival.  
We also observed a high degree of desmoplasia in response to the GLI1/2 
activation, as well as evidence of ascites, both of which are features of advanced 
pancreatic malignancy. However, we failed to detect evidence of full blown 
invasive adenocarcinoma, and metastasis even in mice that survived up to 10 
months of age. There could be multiple explanations for this. One possibility is that 
while GLI1/2 can cooperate with oncogenic KRAS in driving pancreatic 
transformation, additional genetic alterations such as loss of tumor suppressors 
are required for progression to full blown adenocarcinoma, and activation of GLI1/2 
alone does not bypass these requirements. Another possibility is that a majority of 
the mice with aggressive GLI1/2 PanIN lesions die due to pancreatic dysfunction 
before developing adenocarcinoma. A third intriguing possibility is that the strong 
desmoplastic reaction, and massive stromal proliferation induced by GLI1/2 may 
act to restrain further epithelial tumor formation by inhibiting angiogenesis, as 
proposed by some recent studies40.  
Unlike GLI1/2 activation, the deletion of the transcriptional repressor GLI3 from the 
pancreatic epithelium had no effect on the development of the pancreas. Also, Gli3 
deletion did not affect the initiation and progression of PanIN lesions in response 
to oncogenic KRAS activation. The pancreas of P48Cre;LSL-KrasG12D;Gli3fl/fl mice 
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were histologically similar to those of the P48Cre;LSL-KrasG12D mice. As discussed 
previously, GLI3 is primarily a transcriptional repressor. Loss of function mutations 
in Gli3 are known to lead to deregulation of the Hedgehog signaling pathway, and 
are implicated in developmental disorders such as Greig cephalopolysyndactyly 
syndrome and Pallister Hall Syndrome181,182. GLI3 is also known to be mutated in 
a minority of PDAC cases, and Gli3 expression is detected in PDAC cells91,143. Our 
findings imply that GLI3 does not play a significant role in PDAC, and Gli3 deletion 
does not affect pancreatic transformation by KRAS. While our in vivo data 
suggests that unlike GLI1 and GLI2, GLI3 does not play a significant role in 
pancreatic transformation, the difference in the design of the Gli1, Gli2, and Gli3 
genetic experiments may also affect interpretation of our data. Firstly, GLI1 and 
GLI2 are expressed ectopically in our mouse model at levels that are likely higher 
than the physiological levels. Whether the effect of GLI1/2 mediated acceleration 
of PanIN lesions is due to higher levels of expression of the proteins, or due to 
differential transcriptional/post-transcriptional regulation of the ectopically 
expressed transgenes cannot be determined from our experiments. Experiments 
involving genetic ablation of endogenous GLI1 and GLI2 proteins need to be 
conducted in order to further evaluate the role of the individual proteins in 
pancreatic transformation. Also, expression levels of GLI target genes in the 
pancreas of mice with oncogenic KRAS, and oncogenic KRAS with GLI1/2 
activation or GLI3 deletion need to be compared to test whether the lack of 
phenotype with GLI3 deletion is due to the lack of difference in GLI transcriptional 
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activity. If this is the case, then it may imply either that the GLI3 proteins are not 
functional during pancreatic transformation, or that the activity of these proteins is 
not sufficient to counter transcriptional activation by GLI1/2. Another possibility 
could be that while GLI3 may be expressed in PanIN lesions, they may be inactive 
due to lack of post-translational regulation in the pancreatic context. 
Interestingly, bioinformatics analysis using the Oncomine database indicates that 
while GLI1 and GLI3 are upregulated in human PDAC samples compared to 
normal pancreas, GLI2 expression is relatively unchanged. Previous findings in 
human PDAC cells have indicated that GLI2 is undetectable in human PDAC cells, 
and KRAS knockdown leads to a downregulation of GLI1 but not GLI3 in PDAC 
cells143. Although GLI2 may not be expressed at sufficient levels, or in a KRAS 
dependent manner in pancreatic cancer, our data clearly shows that GLI2 is 
capable of playing an important role in promoting pancreatic neoplasia in 
combination with KRAS. Furthermore, our findings that shRNA mediated 
knockdown of GLI1 is sufficient to impair survival of PDAC cells indicates that while 
GLI2 is capable of promoting pancreatic transformation upon ectopic expression, 
GLI1 may be the primary GLI downstream effector of Kras in PDAC. 
Cell-autonomous (non-canonical) GLI activity in PDAC 
As discussed previously, there are multiple possible mechanisms of 
Hedgehog/GLI signaling in pancreatic tumorigenesis. Our study provides strong 
evidence for Hedgehog ligand independent, non-canonical GLI activity in PDAC. 
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Our finding that inhibition of GLI transcription is sufficient to halt KRAS induced 
transformation in pancreas, along with previous reports that the ablation of the 
upstream GLI regulator Smoothened does not affect GLI activity143 suggest cell-
autonomous regulation of GLI in the pancreatic epithelium. Also, while 
Hedgehog/GLI activity in the pancreatic stroma has previously been shown to be 
important, stromal GLI activity is regulated by Hedgehog ligands secreted by the 
epithelium183. This is in contrast to GLI activity in the epithelium, which is regulated 
by oncogenic KRAS. Together, these findings point to differential regulation of GLI 
transcriptional activity in the epithelium and the stroma of the pancreas. 
Our findings that GLI1/2 can accelerate pancreatic neoplasia in the presence of 
oncogenic KRAS, but are not sufficient to initiate tumorigenesis in the absence of 
KRAS activation, suggest a potentially important role in post-translational 
regulation of these transcription factors by KRAS. An earlier report which shows 
that Kras may prevent Gli1 protein degradation in PDAC cells via the 
RAF/MEK/ERK pathway supports this hypothesis184. Furthermore, the inability of 
oncogenic Smoothened (SmoM2) activation to accelerate tumorigenesis suggests 
that canonical Hedgehog signaling upstream of GLI does not play a role in 
regulation of these transcription factors in the pancreatic epithelium. This is in 
contrast to the stroma, where smoothened inhibition can inhibit activity of the GLI 
transcription factors185. These findings highlight context dependent differences in 
regulation of GLI activity in the pancreatic epithelium and the stroma. However, 
while our findings highlight the requirement of GLI in the pancreatic epithelium in 
 124 
 
tumorigenesis, they do not disprove the existence of paracrine Hedgehog signaling 
between the epithelium and the stroma. As discussed previously, there is 
significant evidence that shows paracrine Hedgehog signaling in pancreatic 
cancer, and ligand dependent GLI activity in the stroma. Instead, our findings 
suggest that while Hedgehog dependent GLI activity in the stroma may play a role 
in pancreatic cancer, inhibition of Smoothened and other Hedgehog pathway 
components upstream of GLI may not be sufficient to inhibit tumorigenesis, due to 
the cell autonomous nature of GLI activity in the pancreatic epithelium, and the 
important role played by non-canonical GLI signaling in pancreatic cancer. Our 
conclusion is supported by recent findings which show that treatment with a 
Smoothened inhibitor IPI-296 may not only fail to inhibit pancreatic cancer growth, 
but may also marginally accelerate it, and the failure of Smoothened inhibitors in 
the clinic in treatment of PDAC185,186.  
Unique pancreas specific transcriptional program in PDAC 
In classic Hedgehog/Smoothened dependent cancers, such as BCC, 
medulloblastoma, rhabdomyosarcoma, the GLI proteins are known to drive a 
transcriptional program that controls cell cycle and proliferation, through regulation 
of genes such as CyclinD1, and Myc187,188. However, in the context of PDAC, we 
found that a majority of the genes regulated by GLI were not associated with 
canonical Hedgehog signaling, and that Cyclin D1 and Myc expression was not 
significantly altered upon GLI inhibition, although in our microarray analysis we 
identified several known generic GLI target genes such as GLI1, PTCH1, and 
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FOXA2. These findings suggest that GLI regulates a unique transcriptional 
program in the context of PDAC. Interestingly, we identified a number of genes 
involved in regulation of RAS signaling such as SOS2, RASA1, RIN2, RASSF4, 
and RASSF5 that were downregulated in response to GLI repression. SOS2 is a 
positive regulator of RAS signaling, while RASA1, and RIN2 are negative 
regulators, and RASSF4 and RASSF5 are effectors of RAS induced tumor 
suppression. This suggests the existence of a possible feedback loop between 
RAS and GLI in PDAC. Further, we identified genes involved in regulation of 
PI3K/AKT signaling such as PIK3R1, and PIK3C2B. While our subsequent 
experiments revealed transcriptional regulation of IKBKE by GLI as a mechanism 
of GLI regulation of AKT activity, we have found that regulation of Akt 
phosphorylation by IKBKE is modest compared to AKT regulation by GLI. The 
regulation of PIK3R1, and PIK3C2B may constitute an additional mechanism 
through which Gli may regulate AKT activation. This hypothesis can be tested 
further by conducting shRNA mediated knockdown of these genes and testing its 
effect on AKT phosphorylation. We also identified a number of genes involved in 
regulation of the NF-кB pathway such as IKBKE, TRAF1, TRAF3IP2, MAP3K14, 
and NFKBIE. As discussed previously, the PI3K/AKT and NF-кB signaling 
pathways play an important role in pancreatic tumorigenesis, and are known to act 
downstream of KRAS in regulating processes such as apoptosis, cell proliferation, 
and inflammation. Our findings implicate transcriptional regulation by GLI as a 
potential mechanism through which these pathways are regulated by KRAS in 
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PDAC. Our data also highlights a novel downstream oncogenic program involving 
RAS/PI3K/NF-кB signaling mediating GLI tumorigenic activity. The importance of 
the newly identified candidate Gli target genes can be further evaluated using 
shRNA mediated knockdown in human PDAC cells.  
PI3K/Akt regulation by Gli 
The PI3K/AKT pathway is a major effector of RAS signaling that has been 
implicated in cell transformation146. The mechanisms through which RAS regulates 
PI3K, and subsequently AKT activation have been relatively well characterized101. 
Here, we identified an additional level of mechanistic control of AKT activation in 
KAS dependent PDAC cells. We find that inhibition of GLI using the Gli3T 
repressor in human PDAC cells leads to a significant decrease in AKT 
phosphorylation. Furthermore, we find that treatment with a small molecule 
inhibitor of GLI (Gant61) can lead to a dosage specific decrease in AKT 
phosphorylation in PDAC cells. We also find that in our mouse model, ectopic 
expression of GLI1 in combination with oncogenic KRAS can significantly increase 
AKT phosphorylation. Interestingly, we find that ectopic expression of GLI1 can 
help bypass KRAS induced senescence in PanIN lesions. Activation of the KRAS 
oncogene is known to induce senescence in normal cells, a process which is 
mainly regulated by the MAPK/ERK pathway189, but can be relieved by activation 
of the PI3K/AKT pathway190. Evasion of senescence in response to GLI1 ectopic 
expression may be mediated by the PI3K/AKT pathway in the PanIN lesions. This 
can be tested by conducting staining for β-galactosidase, and 
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immunohistochemistry for AKT phosphorylation on adjacent sections of pancreas 
from P48Cre;KrasG12D;R26-Gli1 mice, and analyzing correlation between 
senescent cells and relative AKT phosphorylation between different PanIN lesions. 
Alternatively, GLI1 can be ectopically expressed, or repressed using shRNA 
mediated knockdown in HPNE cells, which are immortalized human pancreatic 
ductal cells, in combination with oncogenic KRAS to test whether GLI1 enables 
bypass of oncogene induced senescence. 
Regulation of NF-кB signaling by GLI 
As discussed previously, deregulation of NF-кB signaling and its associated 
inflammatory response are the hallmarks of PDAC and have been shown to be 
essential for pancreatic transformation. KRAS oncogenic activation is known to 
drive NF-кB activation in the context of pancreatic cancer. It has been shown that 
KRAS can drive secretion of IL-1 and canonical NF-кB pathway activation through 
transcriptional regulation of AP-144, and non-canonical NF-кB pathway activation 
via regulation of GSK3α127. However, as the NF-кB pathway can be regulated at 
multiple levels191, the link between KRAS and NF-кB signaling in PDAC needs to 
be further explored.  
In our gene expression analysis, we found that the expression of a number of 
regulators of the NF-кB pathway was downregulated in response to repression by 
Gli3T. Furthermore, we found that the expression of an artificial luciferase 
construct carrying p65 binding sites (p65-luciferase) was downregulated by Gli3T 
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expression in PDAC cells. We also found that repression by Gli3T led to a 
significant downregulation in expression of NF-кB target genes and cytokines such 
as BCL2L1, IL-1, and TNF-alpha. This data suggests that GLI may regulate the 
NF-кB pathway in the context of PDAC. The GLI-NF-кB connection is further 
supported by our analysis of Kras-Gli pancreatic tumor models, as well as human 
PDAC samples, although the mechanisms through which GLI may regulate NF-кB 
remain unclear and further studies are clearly needed. Interestingly, we identified 
GLI dependent expression of a number of known NF-кB pathway regulators such 
as the TNF receptor regulator TRAF1, TRAF3IP2, non-canonical NF-кB kinase 
MAP3K14, IKBKE, and also the TAK1 ubiquitinator TRIM8. Alternatively, it is also 
possible that GLI may regulate expression of cytokines, which in turn activate NF-
кB via autocrine signaling. Another possibility is that GLI may regulate expression 
of NF-кB target genes via transcriptional co-activation, therefore functioning as a 
crucial link connecting KRAS signaling, NF-кB pathway activation, and 
inflammatory response during PDAC pathogenesis.  
GLI mediated inflammation in PDAC 
As discussed previously, inflammation has been established to be a critical 
mediator of pancreatic transformation, and chronic pancreatitis is known to be a 
major risk factor in pancreatic cancer124. While previous studies on inflammation 
in PDAC have focused on known regulators of the NF-кB pathway, in our study, 
we demonstrate for the first time, a potential role of GLI signaling in regulation of 
inflammation in PDAC. In our study, we identified GLI dependent expression of a 
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number of pro-inflammatory cytokines such as IL1A, TNFA, CX3CL1, as well as 
other regulators of inflammation such as IKBKE, MAP3K14, IRF1, TRAF3IP2, and 
TRIM8. Other studies have also shown that GLI1 may regulate IL-6 expression in 
the stroma, which activates STAT3 in the pancreatic epithelium through reciprocal 
signaling192. STAT3 activation is known to be an important event in inflammation 
induced pancreatic transformation193. Although previous studies have implicated 
IKKβ, COX2, IL-1α, and p62 in KRAS induced inflammatory response in PDAC, 
GLI transcriptional activation of pro-inflammatory cytokines, and regulators of 
inflammatory response may represent an additional level of regulation of 
inflammation by KRAS in PDAC. Although GLI can activate inflammation in PDAC, 
the link between the downstream effectors of GLI and inflammatory response 
needs to be further explored.   
Therapeutic implications of non-canonical GLI activity in PDAC 
We have demonstrated that in PDAC, cell autonomous activity of Gli transcription 
factors in the epithelium is required for KRAS induced oncogenic transformation. 
We have also established GLI as a critical oncogenic effector of KRAS mediated 
pancreatic transformation and demonstrated regulation of the PI3K/AKT and NF-
кB pathways. Our studies provide proof of concept that therapeutic inhibition of 
GLI should be further evaluated as in development of targeted therapy for PDAC.  
The activity of GLI in the pancreatic epithelium is independent of the upstream 
Hedgehog/Smoothened signaling. Currently, the only Hedgehog pathway 
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inhibitors that have been successful in the clinic are Smoothened inhibitors. The 
Smoothened inhibitor Vismodegib has been approved for treatment of Basal Cell 
Carcinoma, and Smoothened inhibitors are being evaluated for treatment of other 
malignancies194. However, since the GLI activity in the pancreatic tumor epithelium 
is independent of Smoothened, PDAC tumors, which arise from the epithelium are 
refractory to Smoothened inhibition. Unlike the epithelium, the stromal component, 
which makes up a significant mass in PDAC tumors, is sensitive to Smoothened 
inhibition, as the GLI activity in the stroma is regulated by upstream 
Hedgehog/Smoothened signaling183. Hence, in PDAC tumors, treatment with 
Smoothened inhibitors would serve to deplete the stroma, but not the epithelial 
component of the tumors. However, recent studies have shown that stromal 
depletion alone may accelerate tumorigenesis, as the stroma serves to restrict 
angiogenesis40. Hence, targeting Hedgehog signaling in the stroma alone may not 
be beneficial in treatment of PDAC. A better therapeutic strategy may be to target 
the GLI transcription factors instead, as the PDAC epithelium is dependent on the 
activity of these proteins. Another approach may be to identify and target 
downstream effectors of GLI in the tumor epithelium, such as IKBKE, that are 
required for tumorigenicity.  
IKBKE requirement in pancreatic transformation 
IKBKE was first identified as an oncogene in the context of breast cancer where it 
was shown to activate the NF-кB pathway during transformation162. Here, we show 
that IKBKE but not TBK1 is a critical oncogenic effector of KRAS in pancreatic 
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ductal adenocarcinoma both in vitro and in vivo. The identification of IKBKE as a 
novel regulator of pancreatic tumorigenesis opens up new avenues for 
development of targeted therapy for PDAC, as efforts to develop small molecule 
inhibitors of IKBKE are already underway, some of which have shown efficacy in 
vivo163. In this study, we have identified an in vivo requirement for IKBKE signaling 
in the initiation and progression of pancreatic neoplasia. The P48Cre;KrasG12D 
model used in our system mimics initiation of pancreatic neoplasms but not 
progression to adenocarcinoma. While our in vitro studies with human PDAC cells 
highlight a critical requirement for IKBKE in formation of adenocarcinoma, this 
needs to be further evaluated using in vivo models. To achieve this, IKBKE 
knockout can be combined with the “KPC model” of pancreatic adenocarcinoma in 
which KRAS is activated in the pancreatic epithelium along with knockout of TP53. 
Analysis of survival of mice as well as kinetics of PDAC formation can be used as 
an indicator for the involvement of IKBKE in PDAC tumors.  
An alternative mouse model in which PTEN loss is combined with oncogenic KRAS 
can also be used. This would particularly be significant because of an earlier report 
that PTEN deficient PDAC tumors, but not TP53 deficient PDAC tumors are 
vulnerable to small molecule based mTOR inhibition in mouse models113. 
Differences in the role of IKBKE/mTOR in regulation of AKT in the background of 
PTEN loss vs TP53 loss can be evaluated using these two models. The human 
PDAC cell lines used in our study carry mutations in TP53, and we have shown 
these cell lines to be refractory to mTOR inhibition, which can be overcome by 
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IKBKE knockdown. One possibility that needs to be evaluated is that TP53 mutant 
PDAC tumors may be dependent on IKBKE for AKT activation, hence refractory to 
mTOR inhibitors, whereas PTEN deficient tumors may be sensitive to mTOR 
inhibition due to lack of IKBKE dependence. The two mouse models described 
above may be used to test this hypothesis. 
In our in vivo loss of IKBKE function model, we use a whole body knockout allele 
in which IKBKE expression is lost not only in the pancreatic epithelium, but also in 
the tumor microenvironment and in all other tissue types. This is distinct from our 
GLI loss of function model in which we specifically inhibit GLI activity in the 
epithelium. There are various implications of using a whole body knockout instead 
of an epithelial specific knockout. Firstly, a whole body knockout model more 
closely mimics drug based inhibition of IKBKE, as the function of IKBKE is lost not 
in a specific tissue compartment but in all tissues types. In contrast to a whole body 
knockout, an epithelial specific knockout model does not take into account the 
possibility that the particular gene may play a potentially tumor suppressive role 
when expressed in other tissue types, which would have significant implications 
for drug based therapy. Also, the IKBKE knockout mice used in our study are 
healthy, which implies that specific IKBKE inhibition may not be associated with 
severe side effects. 
A limitation of our in vivo model is that it does not distinguish between the 
requirement of IKBKE in the epithelium vs the tumor microenvironment. As 
discussed previously, the tumor microenvironment plays an important regulatory 
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role in PDAC initiation, progression, and response to therapy, and immune cell 
infiltration is a key feature of PDAC tumors. IKBKE is known to play an important 
role in Type I Interferon response via phosphorylation of IRF3, and IRF7, and is 
known to activate the NF-кB pathway in leukocytes121. The possibility that atleast 
part of the antitumor activity of IKBKE inhibition may be due to the role of IKBKE 
in the tumor microenvironment cannot be excluded. To test the significance of 
IKBKE activation in the tumor epithelium, a xenograft model in which IKBKE is 
specifically knockdown using an inducible shRNA in PDAC cell line derived tumors 
can be utilized. An alternative approach using the highly immunocompromised 
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice (NSG)195 can also be used. These mice have 
severe defects in the innate immune system, and lack functional T-cells, B cells, 
and Natural Killer cells. Hematopoeitic Stem Cells (HSCs) isolated from either 
Ikbke knockout or wild type mice can be transplanted into the NSG mice to 
generate IKBKE deficient or IKBKE wild type immune cells. Human PDAC cell lines 
can then be used to generate PDAC tumors in these mice via orthotropic 
transplantation. The differences in tumor growth and pathology between mice 
carrying IKBKE ablation and mice with wild type IKBKE can be evaluated to study 
the stromal contribution of IKBKE in tumorigenesis. 
IKBKE-GLI reciprocal interaction in PDAC 
Our studies have clearly established IKBKE as a GLI target gene downstream of 
KRAS in PDAC cells. Interestingly, we also found evidence to suggest that IKBKE 
can engage in feedback regulation of GLI likely via regulation of GLI1 nuclear 
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localization. GLI1 transcriptional activity can be regulated by phosphorylation by 
different kinases such as S6K1, PKA, and PKC-gamma in both developmental and 
tumorigenic contexts. In addition, PKA phosphorylation has been shown to 
regulate cytoplasmic-nuclear shuttling of GLI1. It is possible that IKBKE may 
regulate subcellular localization of GLI1 via direct. Bioinformatic analysis of the 
GLI1 protein sequence using the Kinexus software reveals candidate IKBKE 
phosphorylation sites at Serine-480, Serine-521, and Serine-538 on GLI1. These 
residues are located in close proximity to the Nuclear Export Signal (NES) of the 
GLI1 protein. Phosphorylation of GLI1 and subsequent inhibition of nuclear export 
has been previously established as a mechanism of GLI1 regulation167. Hence, it 
is possible that IKBKE may activate GLI1 post-translationally by preventing its 
nuclear export, however, further experiments are needed to test this hypothesis. 
IKBKE regulation of GLI1 phosphorylation can be tested preliminarily by testing 
whether co-expression of the two proteins in 293 cells results in differential 
phosphorylation of GLI1 using phos-tag western blot.  Furthermore, although 
immuno-precipitation of GLI1 has been challenging due to lack of a specific high 
quality antibody, recent technological advances such as the CRISPR/Cas9 system 
can be utilized to tag endogenous GLI1 in PDAC cells with a Flag-tag followed by 
immuno-precipitation, and mass spectrometric analysis to test differential 
phosphorylation at various sites on GLI1 in response to IKBKE knockdown. This 
technique can also be used to test subcellular localization of endogenous GLI1 in 
response to IKBKE knockdown or activation. Finally, it is important to consider the 
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possibility that IKBKE regulation of GLI1 may be an indirect event. To test this, an 
in vitro kinase assay can be conducted to test whether IKBKE is capable of 
phosphorylating GLI1 directly. Together, these experiments may provide better 
insight into the mechanism of regulation of GLI1 by IKBKE. 
Signaling pathways regulated by IKBKE in PDAC 
Although IKBKE is a Serine/Threonine kinase that was first identified as an IкB 
kinase, and an activator of NF-кB signaling, it shares only ~30% structural 
homology with the canonical IкB kinases IKKα and IKKβ196. In addition to 
phosphorylating IкB, IKBKE is known to play an important role in activating IRF3 
(interferon regulatory factor 3), and IRF7 (interferon regulatory factor 7) in 
activation of Type I Interferon Response, and IKBKE is also known to directly 
phosphorylate and activate the NF-кB transcription factor c-Rel197. In breast 
cancer, the oncogenic activity of IKBKE can be attenuated by inhibition of NF-кB 
signaling, thus suggesting that IKBKE induced transformation is mainly mediated 
by NF-кB. However, surprisingly, we found that, unlike in breast cancer, the 
oncogenic activity of IKBKE in PDAC is not dependent on its ability to activate NF-
кB signaling, and is likely mediated by alternate mechanisms. In our human PDAC 
cell lines we see only modest regulation of nuclear localization of the NF-кB 
transcription factor p65 by IKBKE. In our in vitro and in vivo systems, we use p65 
nuclear localization in the epithelium as a marker for NF-кB pathway activation. 
While based on our findings it is apparent that IKBKE regulation of NF-кB pathway 
activation is modest, another possibility is that IKBKE may act through a p65 
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independent manner via regulation of C-REL as previously described197. This 
possibility can be further tested by measuring nuclear vs cytoplasmic localization 
of c-REL in response to IKBKE knockdown in PDAC cells. In addition to the NF-кB 
pathway components, IKBKE can phosphorylate other substrates such as CYLD, 
FOXO3a, TRAF2, and AKT198,199,200,172. In particular, IKBKE has been shown to 
directly phosphorylate AKT at both Threonine-308 and Serine-473 in a 
PI3K/mTOR independent manner in biochemical assays; however, its 
physiological and clinical relevance remains unclear.  Our data provide a strong 
evidence that IKBKE is critical for maintaining AKT activity in PDAC. AKT 
phosphorylation at Threonine-308 is normally regulated by PDK1 in response to 
PI3K activation, and Serine-473 phosphorylation is regulated by the mTORC2 
complex. We find that treatment with the mTOR kinase inhibitor Torin1 leads to a 
decrease in AKT phosphorylation at both Threonine-308, and Serine-473 in serum 
starved Panc-1 cells. Although mTORC2 complex does not directly phosphorylate 
AKT at Threonine-308, dephosphorylation of the Serine-473 residue has been 
proposed to cause transient inhibition of phosphorylation at Threonine-308201. This 
effect has been attributed to the ability of the phosphorylated Serine-473 residue 
to provide a docking site for PDK1202. Our findings are consistent with this 
hypothesis as we see loss of AKT phosphorylation at Threonine-308 with mTOR 
inhibition. Although AKT phosphorylation is relatively inhibited by mTOR inhibition, 
we find that a basal level of phosphorylation is maintained even while mTOR is 
inhibited. We find that mTOR inhibition, when combined with shRNA-mediated 
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knockdown of IKBKE in Panc-1 cells leads to a synergistic decrease in 
phosphorylation of AKT at both Serine-473, and Threonine-308. These findings 
suggest that while mTOR certainly plays a role in phosphorylating AKT in PDAC, 
IKBKE is a major contributor to AKT phosphorylation at both Serine-473 and 
Threonine-308, and combined inhibition of mTOR and IKBKE is necessary to 
inhibit AKT activation. Thus, activation of AKT is likely the primary mechanism of 
IKBKE mediated pancreatic tumorigenesis underlying KRAS/GLI activation.  
Combined IKBKE/mTOR inhibition in PDAC 
Although they have been successfully used in the treatment of certain 
malignancies such as Renal Cell Carcinoma, mTOR inhibitors have not been 
effective in treatment of PDAC in the clinic. Resistance to mTOR inhibitors can be 
mediated by multiple mechanisms. Until recently, majority of the mTOR inhibitors 
tested in clinical trials are “Rapalogs” which are analogs of Rapamycin. Rapalogs 
are known to preferentially inhibit mTORC1 complex but are not very effective in 
inhibition of mTORC2, which mediates AKT phosphorylation203. Thus, Rapalogs 
fail to inhibit one of the crucial functions of mTOR which is important in oncogenic 
transformation. Inhibition of mTORC1 can also increase AKT phosphorylation at 
Threonine-308, as S6K, an mTORC1 target normally acts as a negative regulator 
of IGF-1 signaling, and IGF-1 can drive PI3K activation through the activity of 
IRS1204. Hence, Rapalogs are not an ideal choice of treatment in cancers that are 
dependent on AKT activity such as PDAC. mTOR kinase inhibitors, which are 
second generation mTOR inhibitors are considered to be more effective than 
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Rapalogs because they can target both mTORC1, and mTORC2. However, in a 
model of breast cancer, it was recently shown that even mTOR kinase inhibitors 
were unable to suppress AKT reactivation which, in the context of breast cancer, 
was mediated by increased HER2 kinase mediated RTK activation, and 
independent of S6K activity177. In this study, it was shown that combined inhibition 
of mTOR with HER2 led to a decrease in tumor formation in vivo. Hence, in order 
to effectively utilize mTOR inhibitors for treatment of cancer, it is essential to 
identify underlying causes of resistance to the inhibitors, of which there are multiple 
possibilities. 
In our study, we found that mTOR inhibition alone had no effect on the survival of 
human PDAC cell lines, which is consistent with earlier findings in patients. 
Furthermore, we found that although mTOR inhibition in PDAC temporarily led to 
ablation of AKT phosphorylation at both Serine-473 and Threonine-308, 
phosphorylation at both these sites was soon restored in the presence of serum. 
Earlier studies in non-PDAC cell lines have shown that in case of mTOR 
independent AKT reactivation, only phosphorylation at Threonine-308 is restored, 
whereas Serine-473 phosphorylation remains inhibited. Hence, reactivation of 
AKT phosphorylation at both the sites indicates a potentially different, previously 
undiscovered mechanism underlying resistance to mTOR inhibition. Since we 
have found that IKBKE plays a crucial role in AKT regulation in PDAC, we 
evaluated the possibility of IKBKE mediating mTOR-independent AKT reactivation. 
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We found that after shRNA mediated knockdown of IKBKE, AKT rephosphorylation 
at both Threonine-308 and Serine-473 was inhibited.  
Our findings suggest that in the context of PDAC, IKBKE may mediate resistance 
to mTOR inhibition by driving mTOR-independent AKT reactivation. Consistent 
with these results, we also found that IKBKE knockdown led to sensitization of 
Panc-1 cells to mTOR inhibition, and significantly increased apoptosis and 
decreased tumorigenicity in the cells. Our results provide proof of concept that 
combined IKBKE/mTOR inhibition may be beneficial in treatment of PDAC by 
overcoming reactivation of AKT.  
Further in vivo experiments are necessary to test whether combined IKBKE/mTOR 
targeting can lead to inhibition of PDAC tumors in mice. We propose the following 
two approaches:  
1) Utilize the previously described “KPC model”205 with Cre-dependent 
expression of oncogenic KRAS, along with a dominant negative allele of 
Trp53 in the mouse pancreas to mimic human PDAC tumor formation in 
vivo. Once the tumors are established, divide the mice randomly into four 
treatment arms: i) Vehicle alone, ii) ATP competitive mTOR kinase inhibitor 
AZD8055206, iii) IKBKE small molecule inhibitor Amlexanox163, iv) AZD8055 
in combination with Amlexanox. Survival of the mice in different treatment 
arms can be compared to determine potential benefit of treatment 
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2) Generate patient derived xenograft (PDX) models of PDAC via 
subcutaneous engraftation of human PDAC tumors in immunodeficient 
NSG mice207,208. Once PDAC tumors are engrafted, randomly assign the 
mice into four treatment arms, and treat with the IKBKE/mTOR inhibitors as 
described above. Tumor volume measurement can be used as an indicator 
of efficacy of the inhibitors in PDAC treatment. 
Data from the pre-clinical in vivo experiments described above may provide robust 
evaluation of the potential for combined IKBKE/mTOR targeted therapy in 
treatment of PDAC in the clinic. 
Summary (Fig. 4.1) 
In our study, we have identified a critical in vivo requirement for cell autonomous 
GLI transcriptional activity in the pancreatic epithelium for initiation of neoplasia, 
and progression to adenocarcinoma. Using a well established model of pancreatic 
adenocarcinoma, we have provided proof of concept that inhibition of GLI 
transcription factors may be beneficial in treatment of PDAC. Furthermore, we 
have identified a novel PDAC specific transcriptional program regulated by GLI 
that involves activation of the NF-кB and PI3K/AKT signaling pathways, and we 
have established GLI as a mediator of KRAS induced NF-кB and AKT activation. 
We have also identified IKBKE as a transcriptional target of GLI, which plays an 
important role in mediating pancreatic transformation downstream of KRAS. We 
have established that IKBKE engages in feedback regulation of the GLI pathway 
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via regulation of nuclear localization of GLI1. We have found IKBKE to play a 
modest role in activating NF-кB in PDAC, and established IKBKE as a regulator of 
AKT phosphorylation, which plays an important role in mediating AKT reactivation 
post-mTOR inhibition. Furthermore, we have established that IKBKE mediates 
resistance to mTOR inhibition in the context of PDAC and provided proof of 
concept for combined targeting of IKBKE and mTOR in pancreatic cancer. 
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Figure 4.1: Gli-IKBKE signaling in pancreatic adenocarcinoma 
GLI is activated downstream of oncogenic KRAS in the pancreatic tumor 
epithelium, and drives a transcriptional program that leads to AKT and NF-кB 
activation. IKBKE mediates GLI mediated activation of AKT, and partially mediates 
NF-кB activation downstream of Gli. IKBKE and mTOR play a crucial role in AKT 
activation, and IKBKE mediates AKT reactivation post-mTOR inhibition.  
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